Note: Descriptions are shown in the official language in which they were submitted.
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
MEDICAL DEVICE HAVING ANTI-INFECTIVE AND
CONTRACEPTIVE PROPERTIES
Cross Reference to Related Applications
This application claims the benefit under 35 USC 119(e) of copending
Provisional Application No. 60/090,014, filed on June 19, 1998, and is a
continuation-in-
part application of, and claims the benefit under 35 USC 120 of, copending
Application
No. 09/179,233, filed on October 26, 1998, and copending Application No.
09/265,196,
filed on March 10, 1999. These applications and other documents referred to
elsewhere
in the specification of this application are incorporated herein by reference
in their
entireties.
Technical Field of the Invention
The present invention relates to the field of medical devices, and more
particularly to devices having controlled spermicidal, microbicidal, and
virucidal
activities.
Background of the Invention
Introduction of medical devices implanted into the body can lead to serious
nosocomial infections. Implanted medical devices (e.g., venous and arterial
catheters,
neurological prostheses, shunts and stents, joint implant prostheses, urinary
"Foley"
catheters, peritoneal catheters, lead wires to pacemakers, etc.), while
sterilized and
carefully packaged to guard against introduction of pathogens during
implantation, pose
a risk during insertion, and subsequently. During insertion bacteria can be
picked up
from the skin and carried into the insertion site where colonization ensues.
In the case of
urinary catheters, especially those used long term, there is a significant
threat of
microbial growth along the exterior surface of the catheter. This can lead to
chronic
urinary tract infections (CUTI), especially among the elderly. Methods aimed
at
circumventing this problem have included, for example, the coating of implant
devices
with antibiotics before insertion, irngating the implant site with antibiotic,
applying
various antibiotic ointments or antibiotic impregnated sponges near the
exterior opening
by which infection most likely occurs, impregnating the polymer base coating
the
CA 02335055 2000-12-13
WO 99/b5538 PC'f/US99/13898
2
implant device with antibiotics, or treatment of patients systemically with
antibiotics.
However, despite the foregoing attempts and the overuses of antibiotics
involved (with
the attendant risks of developing resistant strains of bacteria), there
remains a need in the
art to mitigate the risk of infection from such devices that are implanted and
have
external environment exposure.
Long term use or misuse of antibiotics often results in the selection of
antibiotic
resistant strains. Hence, in general, systemic antibiotic therapy is ill
advised and
ineffective in warding off CUTI. The secondary side effects of systemic
antibiotic
treatments can also pose a serious risk to many patients. Furthermore, in many
implant
sites, the formation of fibrous tissue around the implant site reduces the
supply of blood
to the implant cavity thereby precluding systemic antibiotic treatment of the
critical
space between the implant and capsular endothelial wall. In the case of a
urinary catheter
(e.g., Foley catheter), antibiotics injected as a coating in the urinary canal
may be washed
out during drainage through leakage of some urine along the urinary tract
outside the
catheter, or resorbed before they can achieve sufficient levels to effectively
kill bacteria
growing within localized regions of the urinary tract.
Aside from implants, there are other commonly acquired infections that cause
significant suffering and health-complications in the general population.
Vaginal
infections, for example, are a frequent cause of health problems in women.
They are a
source of distress and discomfort, and can lead, in some instances, to
sterility, to tubal
ectopic pregnancy, and increased incidences in the transmission of human
immunodeficiency virus (HIV). Chlamydia trachomatis, a sexually transmitted
bacterium, is a serious problem in that it can infect young women of child-
bearing age
without producing any initial overt symptoms, but causing extensive scaring of
the
cervix and permanent loss of fertility. Other serious infections acquired
during, or prior
to pregnancy, but undetected, can result in a multitude of complications to
the unborn
fetus, or lead to pPROM (preterm premature rupture of membranes before the
onset of
labor), a major factor contributing to preterm births.
The most common vaginal infections among women are bacterial vaginosis (BV)
(sometimes referred to as nonspecific vaginitis or Gardnerella-associated
vaginids),
trichomoniasis (sometimes referred to as "trich"), and vulvovaginal
candidiasis (VVC)
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
3
(sometimes referred to as candidal vaginitis, monilial infection, or vaginal
yeast
infection). In infections associated with pPROM, certain women are prone to
colonization by group B Streptococcal strains that pose a particularly serious
threat in
terms of premature delivery and life-threatening complications to the fetus.
Microbicidal treatments for vaginal infections include oral prescription
medications and over the counter (OTC) topical applications, suppositories and
douches.
Topical medications are messy to apply, and require daily applications over a
period of
up to a full week. A difficult problem in the use of OTC medications is that
the infection
may be misdiagnosed and treated inappropriately, resulting in more complicated
problems for the user. Some women, for example, inadvertently treat for yeast
infections
with OTC medications, applying antifungal agents to bacterial infections
(including
STDs) which are not responsive to this mode of treatment, and thus fail to
obtain timely
medical treatment.
These problems underscore the need for better treatment devices and for
devices
designed for prevention of chronic acquired infections associated with implant
insertion
into body cavities, and, for example, the treatment of BV and pPROM.
Additionally, there is a need for female-controlled contraceptive methods that
are
effective against pregnancy and infection. There is widespread recognition of
the burden
of unplanned pregnancies, and the spread of (sexually transmitted diseases)
STDs
(including AIDS) in contributing to human suffering worldwide. Although tubal
ligations and vasectomies provide effective treatments in eliminating
unplanned
pregnancies, neither provides adequate protection against the spread of STDs
(Armstrong, Morbidity Mortality Weekly Report 41:149, 1992). Also, these
methods are
generally irreversible, rendering them unacceptable to many couples who
intend, in the
future, to have children. Hormonal methods of birth control (e.g., Norplant~,
oral
contraceptives, DMPA, vaginal ring), while efficacious in reversibly blocking
unwanted
pregnancies, offer limited protection against STDs (Gates and Stone, Family
Planning
Perspectives 24:75-84, 1992). Spermicidal agents, chiefly nonoxynol-9 and
varying
analogues of this detergent, have a number of drawbacks including irritation
of the
vaginal mucosal tissues, rapid adsorption across mucosal tissues, and
nonspecificity in
disrupting indiscriminately the lipid bilayers of cells. There is also some
evidence that
CA 02335055 2000-12-13
WO 99/ø5538 PCTNS99/13898
4
mucosal lesions of the vagina and cervix, induced by frequent use of nonoxynol-
9,
facilitate the transmission and spread of the HIV virus. In addition, the use
of detergents,
such as nonoxynol-9, in combination with diaphragms, cervical caps and condoms
is
problematic in that they can weaken and degrade the polymers used in the
fabrication of
these barrier devices. Moreover, diaphragms and cervical caps offer only
limited
protection against STDs, and have failure rates in terms of unplanned
pregnancies in the
range of 12 to 24% (Speroff and Danney eds. A Clinical Guide for
Contraception, 2nd
edition. Williams & Wilkins, Baltimore, MD. pp. 229-262, 1996; and Mauk et al.
Contraception 53:329-335, 1996).
Of all the current birth control methods available, the male condom is the
only
device that has FDA labeling indicating it is effective in reducing the
transmission of
STDs. However, the male condom fails to address the need for a female-
controlled birth
control method that further limits exposure to both STDs and unplanned
pregnancies.
An important aspect of an effective contraceptive is that it does not require
frequent attention, or particular skills in its proper use. Indeed, methods
requiring daily
attention prior to intercourse have practical failure rates two-fold higher
(or higher in
some instances) than predicted under ideal use. As an example, the male condom
has an
expected failure rate, in terms of unplanned pregnancies per year, in the
range of 3%, but
a practical failure rate in the range of 14%. This failure rate compares with
the "natural"
withdrawal rate that is in the range of 19%. Of those methods requiring the
least
attention (e.g., sterilization, hormonal methods, and IUD), while effective,
they are
inadequate in providing full protection against the spread of STDs. Further,
many
women dislike long term use of hormonal methods of birth, and they have an
aversion to
the use of IUD's, in part, because of evidence that IUD's can cause pelvic
inflammatory
disease and ectopic pregnancies (e.g., the "Dalkon Shield" experience). Thus,
there is a
need in the art for improved birth control methods that are more effective and
convenient
to use, which are also safe, and which block the transmission of infectious
diseases.
Iodine as an Anti-Infective Agent
In the treatment of infections, elemental iodine is of significance as a
prospective
anti-infective agent. Iodine has intrinsic chemical properties which could be
exploited in
conferring to implant devices novel and e~cacious anti-infective activities in
the
CA 02335055 2000-12-13
WO 99/45538 PCT/US99113898
treatment, and prevention, of opportunistic infections. Iodine has been used
for over 150
years in various formulations as a sterilizing agent.
Iodine exists in several oxidation states including its fully reduced iodide
(I~
state, its diatomic elemental state (I2) (hereafter "elemental iodine"), and
in several
higher oxidation states in combination with oxygen (e.g., hypoiodate (IOC,
iodate (I03~
and periodate (I04~). In aqueous solutions iodide forms an equilibrium complex
with
elemental iodine, yielding soluble tri-iodide (I3') which exhibits neither
significant
microbicidal nor virucidal activity. On the other hand, trace quantities
(e.g., a few ppm)
of elemental iodine are sufficient to cross the lipid bilayer of cells, and
sufficient to kill
micro-organisms through oxidative reactions within their lipid bilayer.
Extensive studies
have also shown that microorganisms are incapable of developing resistance
against
elemental iodine because of its ability to oxidize and intercalate into
multiple sites within
microbes.
Problems in the Delivery and Formulation of Iodine as an Anti-Infective Aeent
Early attempts at improving formulations in extending the shelf life of iodine
solutions designed for anti-infective treatments used alcohol as a carrier in
trapping
iodine in solution. The formulations, referred to as tincture of iodine,
proved
unsatisfactory because the high alcohol content required to retain elemental
iodine in
solution proved, itself, inflammatory. A more satisfactory method of trapping
elemental
iodine in solution evolved with the development of iodophors of iodine (e.g..
complexed
forms of elemental iodine in solution using specific organic binding agents).
Among the
better known iodophors formulated to create a potent anti-infective iodine
solution was
povidone-iodine, also known as Betadine~, a water soluble polyvinylpyrrolidone
organic
polymer mixed with iodide and elemental iodine. In this formulation elemental
iodine
binds to the hydrophobic polyvinylpyrolidone backbone as well as to the
cationic
pyrroie nitrogen in the form of a tri-iodide complex. The rationale to this
formulation
was that elemental iodine would be available through equilibrium with loosely
bound
(e.g., "available") iodine complexed to polyvinylpyrrolidone.
Elemental iodine (i.e., free I2) is actually only a very small fraction of the
total
iodine in commercial anti-infective formulations, such as povidone-iodine. 10%
povidone-iodine, for example, is formulated at ~ 1 % total "available" iodine
(e.g.,
CA 02335055 2000-12-13
WO 99/b5538 PCT/US99/13898
6
10,000 ppm), whereas its elemental iodine concentration varies from ~ 0.8 to
1.2 ppm
(Ellenhorn's Medical Toxicology: Diagnosis and Treatment ofHuman Poisoning,
2"a
edition). While this level of elemental iodine is marginally effective as a
microbicide, it
comes at a cost. LeVeen et ai. (Surgery, Gynecology & Obstetrics 176:183-190,
1993)
have pointed out several deficiencies in povidone-iodine formulations
including the
tradeoff of a very low elemental iodine level (e.g., approx. 1 ppm). Low
elemental
iodine makes povidone-iodine relatively ineffective as an anti-infective agent
except
against extremely sensitive bacteria. Povidone-iodine solutions also fail to
treat severe
vaginitis, and cause complications associated with formation of granulomas in
wounds,
as a result of residual polyvinylpyrrolidone in formulations applied to the
wound site.
Additionally, elemental iodine is not available in sufficient concentrations
in
commercial formulations to use as a spermicidal agent. WHO (the World Health
Organization) defines standards for spermicide testing and requires that a
spermicide
completely immobilize all sperm with which it comes into contact within 20
seconds.
These standards reflect the fact that sperm spend a very short time (seconds)
within the
vaginal vault following ejaculation into the vagina before passing through the
cervical os.
Thus, an effective spermicide must be capable of rapidly immobilizing sperm
before they
can pass through the cervical os and into the uterus. These WHO criteria are
an
important standard for testing contraceptive devices. Others have sought to
use iodine
formulations in birth control applications either in the form of povidone-
iodine, in
complexes with polyurethane, or in combination with nonoxynol-9, but have
failed to
demonstrate adequate spermicidal activity in accordance with the standards
defined by
WHO. For example, povidone-iodine in the range of 1 % and higher total iodine
was
found to require upwards of 10 minutes exposure to semen samples before the
sperm lost
motility, whereas 0.1 % and lower concentrations of povidone-iodine failed, or
even
stimulated, sperm motility (Pfannschmidt et al. US Patent 5,545,401). Several
patents
have disclosed the use of povidone-iodine (or iodine complexed with
polyurethane) as a
spermicide or in combination with ionic or nonionic detergents (see, for
example, U.S.
Patents 5,545,401; 5,577,514; '4,922,928; 5,156,164; and 5,466,463). However,
there is
no evidence that iodine formulations of the type disclosed, in any fashion,
confer enough
CA 02335055 2000-12-13
WO 99165538 PCT/US99/13898
7
spermicidal activity sufficient to put these formulations into practice
according to WHO
criteria.
Other characteristics of povidone-iodine also make it impractical to use as an
intravaginal anti-infective agent, even in combination with other spermicidal
agents. For
example, the intense brownish-red coloration of this solution makes it
unattractive
esthetically and unacceptable to users. In addition, the use of povidone-
iodine
formulations, in combination with such spermicidal detergents as nonoxynol-9,
is
problematic in that iodine causes the detergent moiety to precipitate out of
solution. In
the presence of quaternary ammonium detergents, both iodine and triiodide form
insoluble complexes in binding to the quaternary ammonium moiety that causes
the
detergent to precipitate out of solution. Hence, combining iodine with the
common
spermicidal detergent, nonoxynol-9, related polyunsaturated detergent
polymers, or
cationic quaternary ammonium detergents produces products that lose their
spermicidal
properties through chemical modification and precipitation from solution.
An attempt to circumvent problems associated with formulations containing
povidone-iodine in recognition of the fact that elemental iodine is the active
agent
conferring anti-infective activity was made by Shikani and Domb (J. Amer.
College of
Surgeons 183:195-200, 1996; U.S. Patent 5,762,638). The authors coated plastic
implant
devices with layers of elemental iodine dissolved in a polymer base in such a
manner so
as to cause adherence of the iodine-polymer on the surface of the implant
device. This
approach has several limitations. It is costly and, as pointed out by Shikani
and Domb, it
is limited to polymeric implant devices which can tolerate solvents used in
dissolving the
iodine-loaded polymer coating, and which are chemically compatible in forming
a strong
and intact bond between the iodine impregnated polymer coating and implant
polymer
substratum. Polymers which swell in biological fluids (a common phenomenon)
also
cannot be used in this technology because swelling leads to a rupture of the
coated outer
layer, and thereafter a failure of the controlled release rates of the
impregnated iodine to
the surrounding sites requiring anti-infective treatment.
Within the body, a variety of naturally occurring oxidants are produced which
function as anti-infective agents. The major source of oxidizing activity
accounting for
development of anti-infective activities in the body can be traced to the
initial formation
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
8
of superoxide and hydrogen peroxide through a variety of oxidizing pathways.
These
initial oxidants are known to catalyze in the presence of halides. trace
metals, thiocyanate
(a natural constituent of particular abundance in saliva believed to confer to
the mouth
certain unique antimicrobial properties when converted to hypothiocyanite),
and amines,
a cascading armada of anti-infective products including (in addition to
superoxide and
hydrogen peroxide) hydroxyl radicals, hypohalites (e.g., hypochlorite,
hypobromite),
haloamines (e.g., chloramine), hypothiocyanite, and nitric oxide. all of which
have been
shown to exhibit varying degrees of antimicrobial activity (Klebanoff, S.J.
and Clark,
R.A. ( 1978) in The Neutrophil: Function and Clinical Disorders, North-Holland
Publishing Company, Amsterdam; Halliwell, B. and Gutteridge, J.M. (1990) Role
of
Free Radicals and Catalytic Metal Ions in Human Disease: An Overview. Meth.
Enzymol.
186, 1-85; Southorn, P.A. and Powis, G. (1988) Free Radicals in Medicine. I.
Chemical
Nature of Biological Reactions. May Clinic Proc. 63, 390-498; Pryor, W.A.,
ed., in Free
Radicals in Biology, Academic Press, New York, 1976-1984), Vol. 1-6;
Klebanoff, S.J.
(1991) in Peroxidases in Chemistry and Biology (Everse, J., Everse, K.E. and
Grisham,
M.B., eds.), pp. 1-35, CRC Press, Boca Raton; Tenovuo, J. (1997) Salivary
Parameters
of Relevance for Assessing Caries Activity in Individuals and Populations.
Community
Dent. Oral Epidemiol. 25: 82-6; Carlsson, J., Edlund, M.B. and Hanstrom, L.
(1984)
Bactericidal and Cytotoxic Effects of Hypthiocyanite-Hydrogen Peroxide
Mixtures.
Infection & Immunity 44: 581-6.). Elemental iodine, while also easily formed
in the
presence of these naturally occurnng oxidants, ordinarily is not formed as an
anti-
infective in the body defenses against microorganisms because the
concentration of
iodide in tissues and body fluids, with the exception of the thyroid gland,
are too low
relative to chloride, the most abundant halide found in body tissues and
fluids. Thus
hypochlorite and chloramines are produced within the body in far greater
abundance than
hypoiodite and iodamines under physiological conditions.
Accordingly, it can be appreciated from the above observations that there is a
need for fabricating medical devices such as cannulas, catheters and the like,
and other
types of implants with microbicidal, virucidal, or spermicidal activity, aimed
at treating
ongoing infections, preventing infections that gain access through the
implanted devices,
or providing contraceptive and anti-infective properties, with improved
performance over
CA 02335055 2000-12-13
WO 99/!5538 PCT/US99/13898
9
current antibiotic, iodophor treatments, or contraceptive systems.
Summary of the Invention
The present invention provides a medical device comprising a polymeric matrix
containing an oxidant producing component within the matrix which is stable at
least
until the device is contacted by water. The term stable as used herein should
be
understood to mean that the device will not produce an oxidant at least until
the device is
contacted by water and the oxidant producing component is solvated. The water
may be
provided by exposing the device to body fluids during use, or by wetting the
device just
prior to use. The invention provides an anti-infective medical device due to
the
production of an anti-infective oxidant, which in one embodiment, provides
contraceptive spermicidal activity. The term medical device should be
understood to
include a variety of devices including catheters, dressings, implants,
prostheses,
contraceptive barriers, and gloves.
The anti-infective medical device of the invention produces an oxidant having
anti-infective properties due to its oxidative activity. The anti-infective
oxidant produced
by the oxidant producing component has microbicidal and virucidal activity,
and in one
embodiment, spermicidal activity. Suitable anti-infective oxidants include
elemental
iodine, hydrogen peroxide, superoxide, nitric oxide, hydroxy radical,
hypohalites,
haloamines, thiocyanogen, and hypothiocyanite. The anti-infective oxidants are
produced by the oxidation, reduction, or hydrolysis of the oxidant producing
component.
In the case of elemental iodine, the oxidant producing component is an iodine-
containing salt which is oxidized or reduced, to produce elemental iodine. A
source of
protons is generally required to drive the oxidation or reduction of iodine-
containing salt
to elemental iodine. Iodine-containing salts suitable for use in the invention
include
iodides, which oxidize to elemental iodine, and iodates, which reduce to
elemental
iodine. Suitable iodides include any of the iodides of alkali and alkaline
earth metals,
such as sodium iodide, potassium iodide, calcium iodide, and barium iodide.
Suitable
iodates include iodates of alkali metals such as sodium iodate, potassium
iodate, and
iodine pentoxide. In the case of iodates, the iodate may act as both a source
of iodide,
and an oxidizing agent which oxidizes iodide to elemental iodine.
CA 02335055 2000-12-13
WO 99/5538 PCT/US99/13898
In the case of hydrogen peroxide as the anti-infective oxidant, a variety of
suitable oxidant producing compounds may be used including peroxy acid
precursors and
hydrogen peroxide addition compounds. such as percarbamides, perborates,
percarbonates, persulfates and peroxides. which hydrolyse or solvate to
produce
hydrogen peroxide. Alternatively, substrate oxidoreducatases may be used in
which
hydrogen peroxide is formed as either a direct or an indirect product of the
catalytic
reduction of molecular oxygen. In the case of hypohalite as the anti-infective
oxidant,
the oxidant producing component comprises a halide-containing compound
oxidized by
an oxidizing agent to produce the hypohalite. Similarly, a thiocyanogen or
hypothiocyanite anti-infective oxidant can be produced by the oxidation of a
thiocyanate.
A variety of suitable oxidizing agents may be used to oxidize the oxidant
producing component, including iodine oxide salts, peracids, and substrate
oxidoreducatases. Suitable iodine oxide salts include alkali or alkaline earth
metal
iodates such as potassium iodate, sodium iodate or calcium iodates, and iodine
pentoxide. Suitable peracids include perborates and organic peroxyacids.
A variety of suitable reducing agents may be used to reduce the oxidant
producing component. For example, where the oxidant producing component is an
iodate, any iodate oxidizable substrate such as ascorbate, thiols, and organic
aldehydes
may provide the reducing equivalents to reduce iodate to elemental iodine. In
the case of
intravaginal use, these reducing agents may be present in the intracorporeal
environment
in which the medical device is used.
A variety of suitable proton producing agents may be used including an
anhydride which upon exposure to water spontaneously hydrolyzes to an acidic
product,
or an enzyme acting on a substrate which catalyzes formation of an acid
product. In a
presently preferred embodiment, the proton producing agent is selected from
the group
consisting of iodine pentoxide, an organic or inorganic acid, and enzyme
oxidase, and an
anhydride such as succinic anhydride, malefic anhydride, succinyl malefic
anhydride and
acetic anhydride.
In one aspect of the invention, the anti-infective medical device comprises a
polymeric matrix which contains all the oxidant precursor components)
necessary to
produce the anti-infective oxidant, except for water to solvate the
component(s), so that
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
11
the oxidant producing compound is stable until the device is contacted by
water. In
accordance with the invention, the oxidant precursor components) may consist
of one
component, namely an oxidant producing component which merely requires
hydrolysis
or solvation to produce the oxidant. Alternatively, the oxidant precursor
components)
contained in the polymeric matrix may include an oxidant producing component
and one
or more of an oxidizing agent, a reducing agent, and a proton source.
In another aspect of the invention, the anti-infective medical device
comprises a
polymeric matrix which does not contain one or more reactants required for
reacting with
the oxidant producing component to form the oxidant. For example, an oxidizing
or
reducing agent, or a reactant which forms the oxidizing or reducing agent, or
a proton
source may be absent from the polymeric matrix, so that the oxidant producing
component is stable until contacted by water and by the oxidizing or reducing
agent,
and/or proton source. The missing reactants may be provided by the body fluid
which
contacts the device during use. For example, hydrogen peroxide as an oxidizing
agent
may be produced by a substrate oxidase enzyme in which one or both of the
substrate and
the enzyme is provided by the body fluid. Thus, device stability is achieved
by
providing a device which lacks one or more reactants (i.e., water, oxidizing
or reducing
agents, and protons) required to produce the anti-infective oxidant. The
medical device
of the invention may provide sustained release of the oxidant, so that the
anti-infective or
spermicidal activity of the medical device is provided over a length of time
depending on
a variety of factors including the concentration and nature of the oxidant
precursor
component(s), and the configuration of the polymeric component containing the
oxidant
precursor component(s).
A variety of suitable polymers may be used as the polymeric matrix including
thermoplastic polymers, thermosetting polymers, and hydrogels. Polymeric
materials
typically used in medical devices which are suitable for use in the invention
include
silicone, polyolefins, polyamides, polyesters, polyethers, polyurethanes,
polycarbonates,
polyacrylates, and fluoropolymers. Suitable hydrogels include polyacrylates,
celluloses,
and starch. Particles of the oxidant producing component, and optionally one
or more of
a reducing agent, oxidizing agent, and proton source, are typically added to
the polymeric
material (or to elastomers of a two-component formulation), which is then
processed by a
CA 02335055 2000-12-13
WO 99/b.5538 PCTNS99/13898
12
variety of suitable methods such as molding or extruding into the medical
device. In the
case of a two-component elastomer formulation such as a polymethylvinyl
siloxane (Part
A) and the second catalytic formulation comprising a platinum catalyst and
methyl
hydryl siloxane (Part B), particles of the oxidant producing component,
oxidizing agent
and proton sources may be added separately to either Part A or B of the two-
component
elastomers in forming master batches which upon mixing together result in
cured
polymers containing the anti-infective and spermicidal formulation entrapped
within the
cured polymer matrix. Alternatively, in thermomelt polymers, the solid
particle
formulations are typically mixed into the polymer base at, or slightly above,
its melting
point where the polymer takes on a liquid state, and then entrapped as a
dispersion in the
polymer matrix as the polymer is then cooled below its melting point. The
oxidant
producing component may be contained throughout the polymeric material of the
anti-
infective medical device. Alternatively, a layer of the polymeric material
containing the
oxidant producing component may be provided as a coating on a surface of the
medical
device. For example, a catheter having a shaft and a lumen therein may have a
the
oxidant producing component throughout the shaft, or alternatively, may have a
layer of
polymeric material containing the oxidant producing component on at least one
of an
inner surface and an outer surface of the catheter shaft. The configuration
used will
depend on a variety of factors including the desired concentration of oxidant,
the
polymeric material, and application. For example, a layer of polymeric
material
containing the oxidant producing component may be applied as a coating to a
medical
device formed of a nonpolymeric material or a polymeric material which has
characteristics or processing conditions which make adding the oxidant
producing
component to the polymeric material undesirable, or impractical.
In a first embodiment, the present invention provides an implantable device
having anti-infective activity, comprising a solid hydrophobic polymeric
material
suitable for medical implantation containing therein and further comprising a
dry
oxidant-generating formulation, which in a presently preferred embodiment is
an iodine-
generating formulation, and wherein the dry iodine-generating component is a
dry
mixture of an iodine salt selected from the group consisting of anhydrous
potassium
iodide, anhydrous sodium iodide, and combinations thereof, and an oxidizing
agent,
CA 02335055 2000-12-13
WO 99/55538 PCTNS99/13898
13
wherein the oxidizing agent is selected from the group consisting of anhydrous
alkali
iodine oxide salts, inorganic or organic peracids, a H202 generating oxidase
enzyme, and
combinations thereof. Preferably, the solid polymeric material is a silicone
elastomer.
Preferably, the concentration of anhydrous potassium iodide, anhydrous sodium
iodide, or both is from about 0.01 % to about 16% (by weight) of the solid
polymeric
material. Preferably, the anhydrous alkali iodine oxide salts are selected
from the group
consisting of anhydrous sodium iodate, iodine pentoxide, and combinations
thereof.
Preferably, inorganic or organic peracids are selected from the group
consisting of
perborates, organoperoxy acids, and combinations thereof. Most preferably the
inorganic
or organic peracids, if the only oxidizing agent present in the formulation,
are provided at
a concentration of from about 0.01 % to about 16% (by weight) of the solid
polymeric
material. Preferably, the Hz02 generating oxidase enzyme is selected from the
group
consisting glucose oxidase, diamine oxidase, and combinations thereof. The
term
glucose oxidase as used herein should be understood to mean D-glucose:oxygen 1-
oxidoreductase; EC 1.1.3.4, and the term diamine oxidase as used herein should
be
understood to mean amine:oxygen oxidoreductase[deaminating] [pyridoxal-
containing];
EC 1.4.3.6. Most preferably the HZO2 generating oxidase enzyme further
comprises a
peroxidase enzyme. The term peroxidase enzyme should be understood to mean
donor:hydrogen-peroxide oxidoreductase; EC 1.1 i.1.7. Preferably, the H202
generating
oxidase enzyme, if the only oxidizing agent present in the formulation, is
present at a
concentration of from about 0.01 % to about 2.5% (by weight) of the solid
polymeric
material. Most preferably, the glucose oxidase (D-glucose:oxygen 1-
oxidoreductase; EC
1.1.3.4) is present at a concentration of at least 0.01 % by weight of the
solid polymeric
material, wherein the specific activity of glucose oxidase is in the range of
2,000 to
200,000 IU per gram of solid (i.e., per gram of glucose oxidase) and a
peroxidase
(donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) is present at a
concentration of
at least 0.01% by weight of the solid polymeric material wherein the specific
activity of
peroxidase is in the range of 250,000 to 330,000 IU per gram of solid, with
the proviso
that the sum concentration of a combination of oxidase and peroxidase enzymes
is within
the range of from about 0.01 % by weight to about 2.5% by weight of the solid
polymeric
material. Most preferably, the diamine oxidase (amine:oxygen
CA 02335055 2000-12-13
WO 99/45538 PCT/US99/13898
14
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6) is present in
the
formulation at a concentration of at least 0.01 % by weight of the solid
polymeric
material, wherein the specific activity of diamine oxidase is in the range of
50 to 800 IU
per gram of solid, and a peroxidase (donor:hydrogen-peroxide oxidoreductase;
EC
1.11.1.7) is present at a concentration of at least 0.01 % by weight of the
solid polymeric
material, wherein the specific activity of peroxidase (donor:hydrogen-peroxide
oxidoreductase; EC 1.11.1.7) is in the range of '_' X0,000 to 330,000 IU per
gram of solid,
with the proviso that the concentration of the H,OZ generating oxidase enzymes
is within
the range of from about 0.01 % to about 2.5% b~- weight of the solid polymeric
material.
Preferably, the formulation further comprises a desiccant to stabilize the
iodine salts from
absorbing moisture from the atmosphere and prematurely solvating and forming
iodine.
Preferably a desiccant is selected from the group consisting of a dry powder
mixture of
from about 1 % to about 10% (by weight) polyvinylpyrrolidone, CaCl2 and
combinations
thereof.
In a second embodiment, the present invention further provides a hydrogel anti-
infective or contraceptive device, comprising a hydrogel agent and an iodine-
generating
formulation, wherein the iodine generating formulation comprises an iodide and
an
oxidizing means, wherein the iodide is selected from the group consisting of
potassium
iodide, sodium iodide, and combinations thereof. wherein the oxidizing means
is present
in an amount sufficient to release iodine from the iodide.
Preferably, the oxidizing means is selected from the group consisting of
alkali
iodine oxide salts, peracids, H202-generating enzyme oxidases, and
combinations
thereof. Most preferably, the alkali iodine oxide salts are sodium iodate, or
iodine
pentoxide or both. Most preferably, the peracids are perborates, peracetates,
or both.
Most preferably, the H2O2 generating enzyme oxidases are selected from the
group
consisting of glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4)
or
diamine oxidase (amine:oxygen oxidoreductase[deaminating] [pyridoxal-
containing]; EC
1.4.3.6) and combinations thereof. Preferably, the H202 generating enzyme
oxidases
optionally includes a peroxidase enzyme. Preferably, the peroxidase enzyme is
donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7.
Preferably, the hydrogel agent is a polycarboxylic or polyhydroxyl complex
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
1S
polymer selected from the group consisting of linear polyacrylates, cross-
linked
polyacrylates, hydroxyalkyl celluloses, polycarboxyalkyl celluloses, water
soluble
celluloses, polyethylene alcohols, vinyl alcohols, chitosan polymers, salts of
alginic acid,
and combinations thereof. Preferably, the hydrogel agent is made up to not
less than
about 0.2% (by weight) in water, and not more than about S% by weight in
water. Most
preferably, the hydrogel agent is about 2% by weight of the formulation.
Preferably, the
pH of the formulations is from about pH 3.0 to about pH 6.5. Most preferably,
the pH is
about 4Ø
Preferably, the concentration of iodide in the hydrogel device formulation is
from
about 0.1 mM to about 200 mM. Preferably, the hydrogel device formulation
oxidizing
means is present in the formulation at a concentration from about 0.1 mM to
about 200
mM when the oxidizing means is an alkali oxide of iodine or a peracid.
Preferably, the
hydrogel device formulation oxidizing means is present in the formulation at a
concentration from about 2 p.g/ml to about S00 p.g/ml when the oxidizing means
is a
H2O2 generating enzyme oxidase. Preferably, the glucose oxidase (D-
glucose:oxygen 1-
oxidoreductase; EC 1.1.3.4) made up at a specific activity is in the range of
2,000 to
200,000 IU per gram of solid, or diamine oxidase (amine:oxygen
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6) is made up at
a
specific activity is in the range of SO to 800 IU per gram of solid.
Preferably, the
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) enzyme is
present at
a concentration of from about 2 pg/ml to about S00 p,g/ml when its specific
activity is in
the range of 250,000 to 330,000 IU per gram of solid.
The present invention further provides a hydrogel anti-infective and
contraceptive
device, comprising a hydrogel member having a circular shape suitable for
vaginal
insertion and retention in the cervical region and formed by a process
comprising:
(a) admixing a hydrogel-forming formulation with an aqueous iodine-generating
formulation, wherein the iodine generating formulation comprises an iodide and
an
oxidizing means, and wherein the hydrogel-forming formulation comprises a
hydrogel
agent, wherein the iodide is selected from the group consisting of potassium
iodide,
sodium iodide, and combinations thereof, wherein the oxidizing means is
present in an
amount sufficient to release iodine from the iodide, and wherein the hydrogel
agent is
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/t3898
16
selected from the group consisting of linear polyacrylates or cross-linked
polyacrylates,
hydroxyalkyl celluloses, polycarboxyalkyl celluloses, water soluble cellulose,
polyethylene or vinyl alcohols, chitosan polymers, salts of alginic acid, or
combination
thereof, to form a hydrogel device formulation; and
(b) pouring the hydrogel device formulation into a mold to form a semi-solid
in a
shape of the mold, wherein the mold forms a ring-shape or a disc-shape.
The hydrogel-forming formulation may be provided with a viscosity augmentor
when desired, as for example in the the case of a vaginal device for
contraception and
infections. Most preferably, the viscosity augmentor is a polycarboxylic or
polyhydroxyl
complex polymer selected from the group consisting of linear polyacrylates,
cross-linked
polyacrylates, hydroxyalkyl celluloses, polycarboxyalkyl celluloses, water
soluble
celluloses, polyethylene alcohols, vinyl alcohols, chitosan polymers, salts of
alginic acid,
and combinations thereof. Preferably, the viscosity augmentor is made up to
not less
than about 0.2% (by weight) in water, and not more than about S% by weight in
water.
Most preferably, the viscosity augmentor is about 2% by weight of the aqueous
formulation. Preferably, the pH of the hydrogel-forming device formulation is
from
about pH 3.0 to about pH 6.5. Most preferably, the pH is about 4Ø
Preferably, the anti-infective device that is either the hydrophobic polymer
embodiment or the hydrogel embodiment is shaped to either conform to a body
cavity, a
specific implant design, or a thin sheet of not less than 0.1 mm in thickness
or greater
than 10 mm in thickness. Most preferably, a vaginal implant shape is formed
into a
circular shape suitable for vaginal insertion and retention in the cervical
region. Suitable
device circular shapes are ring, concave disc, and tampon. In the ring
configuration
designed to fit near the fornix between the vaginal wall and cervix, the
device should
have an outer diameter of from about 3.0 cm to about 7.0 cm. Most preferably,
the outer
diameter is from about 5.6 cm to about 6.0 cm. The inner, hollow core of the
ring
diameter should range from about 2.0 to about 6.0 cm, allowing for a ring of
from about
0.5 to 1.5 cm in thickness, most preferably exhibiting a hollow core diameter
of from
about 4.6 to 5 cm, and a ring of from about 0.8 to about 1.2 cm in thickness.
In a third embodiment, the present invention further provides a bilayer
hydrogel
anti-infective device, comprising a first bilayer member comprising a hydrogel
agent and
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
17
a first component of an iodine-generating formulation and a second bilayer
member
comprising a hydrogel agent and a second component of an iodine-generating
formulation. wherein the first component of the iodine generating formulation
comprises
an iodide and the second component of the iodine-generating formulation
comprises an
oxidizing means, wherein the iodide is selected from the group consisting of
potassium
iodide, sodium iodide, and combinations thereof, wherein the oxidizing means
is present
in an amount sufficient to release iodine from the iodide, and wherein the
hydrogel agent
is selected from the group consisting of linear polyacrylates or cross-linked
polyacrylates, hydroxyalkyl celluloses, polycarboxyalkyl celluloses, water
soluble
cellulose, polyethylene or vinyl alcohols, chitosan polymers, salts of alginic
acid, or
combination thereof.
Preferably, the oxidizing means is selected from the group consisting of
alkali
iodine oxide salts, peracids, H20z-generating enzyme oxidases, and
combinations
thereof. Most preferably, the alkali iodine oxide salts are potassium or
sodium iodate,
iodine pentoxide or both. Most preferably, the peracids are perborates,
peracetates, or
both. Most preferably, the H202 generating enzyme oxidases are selected from
the group
consisting of glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4)
or
diamine oxidase (amine:oxygen oxidoreductase[deaminating] [pyridoxal-
containing]; EC
1.4.3.6) and combinations thereof. Preferably, the H202 generating enzyme
oxidases
optionally includes a peroxidase enzyme. Preferably, the peroxidase enzyme is
donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7.
Preferably, the hydrogel agent is a polycarboxylic or polyhydroxyl complex
polymer selected from the group consisting of linear polyacrylates, cross-
linked
polyacrylates, hydroxyalkyl celluloses, polycarboxyalkyl celluloses, water
soluble
celluloses, polyethylene alcohols, vinyl alcohols, chitosan polymers, salts of
alginic acid,
and combinations thereof. Preferably, the hydrogel agent is made up to not
less than
about 0.2% (by weight) in water, and not more than about 5% by weight in
water. Most
preferably, the hydrogel agent is about 2% by weight of the formulation of
either the first
or the second component. Preferably, the pH of the formulations is from about
pH 3.0 to
about pH 6.5. Most preferably, the pH is about 4Ø
Preferably, the concentration of iodide in the bilayer hydrogel device
formulation
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
I8
is from about 0.1 mM to about 200 mM. Preferably, the bilayer hydrogel device
formulation oxidizing means second component is present at a concentration
from about
0.1 mM to about 200 mM when the oxidizing means is an alkali oxide of iodine
or a
peracid. Preferably, the hydrogel device formulation oxidizing means second
component
is present at a concentration from about 2 pg/ml to about S00 pg/ml when the
oxidizing
means is a H202 generating enzyme oxidase. Preferably, the glucose oxidase (D-
glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) made up at a specific activity is
in the
range of 2,000 to 200,000 IU per gram of solid, or diamine oxidase
(amine:oxygen
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6) is made up at
a
specific activity is in the range of SO to 800 IU per gram of solid.
Preferably, the
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) enzyme is
present at
a concentration of from about 2 pg/ml to about 500 p,g/ml when its specific
activity is in
the range of 250,000 to 330,000 IU per gram of solid.
In a fourth embodiment, the present invention further provides a coated
implantable device having anti-infective activity, comprising an implantable
medical
device formed of a polymeric material having an anti-infective coating
thereon, wherein
the anti-infective coating comprises a solid hydrophobic polymeric material
suitable for
medical implantation containing therein and further comprising a dry iodine-
generating
formulation, and wherein the dry iodine-generating component is a dry mixture
of an
iodine salt selected from the group consisting of anhydrous potassium iodide,
anhydrous
sodium iodide, and combinations thereof, and an oxidizing agent, wherein the
oxidizing
agent is selected from the group consisting of anhydrous alkali iodine oxide
salts,
inorganic or organic peracids, a H20Z generating oxidase enzyme, and
combinations
thereof. Preferably, the solid polymeric material is a silicone elastomer.
Preferably, the concentration of anhydrous potassium iodide, anhydrous sodium
iodide, or both is from about 0.01 % to about 16% (by weight) of the anti-
infective
coating. Preferably, the anhydrous alkali iodine salts are selected from the
group
consisting of anhydrous,sodium iodate, iodine pentoxide, and combinations
thereof.
Preferably, inorganic or organic peracids are selected from the group
consisting of
perborates, organoperoxy acids, and combinations thereof. Most preferably the
inorganic
or organic peracids, if the only oxidizing agent present in the formulation,
are provided at
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
19
a concentration of from about 0.01% to about 16% (by weight) of the anti-
infective
coating material. Preferably, the H202 generating oxidase enzyme is selected
from the
group consisting of glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC
1.1.3.4),
diamine oxidase (amine:oxygen oxidoreductase[deaminating] [pyridoxal-
containing]; EC
1.4.3.6), and combinations thereof. Most preferably the H20z generating
oxidase
enzyme further comprises a peroxidase (donor:hydrogen-peroxide oxidoreductase;
EC
1.11.1.7) enzyme. Preferably, the Hz02 generating oxidase enzyme, if the only
oxidizing
agent present in the formulation, is present at a concentration of from about
0.01 % to
about 2.5% (by weight) of the anti-infective coating material. Most
preferably, the
glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) is present at
a
concentration of at least 0.01% by weight of the anti-infective coating
material, wherein
the specific activity of glucose oxidase is in the range of 2,000 to 200,000
IU per gram of
solid and a peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7)
is present
at a concentration of at least 0.01% by weight of the solid polymeric material
wherein the
specific activity of peroxidase is in the range of 250,000 to 330,000 IU per
gram of solid,
with the proviso that the sum concentration of a combination of oxidase and
peroxidase
enzymes is within the range of from about 0.01 % by weight to about 2.5% by
weight of
the anti-infective coating material. Most preferably, the diamine oxidase
(amine:oxygen
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6) is present at
a
concentration of at least 0.01 % by weight of the anti-infective coating
material. wherein
the specific activity of diamine oxidase is in the range of 50 to 800 IU per
gram of solid,
and a peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) is
present at a
concentration of at least 0.01 % by weight of the anti-infective coating
material, wherein
the specific activity of peroxidase is in the range of 250,000 to 330,000 IU
per gram of
solid, with the proviso that the concentration of the H2O2 generating oxidase
enzymes is
within the range of from about 0.01% to about 2.5% by weight of the anti-
infective
coating material. Preferably, the anti-infective coating further comprises a
desiccant to
stabilize the iodine salts from absorbing moisture from the atmosphere and
prematurely
solvating and forming free iodine. Preferably the desiccant is selected from
the group
consisting of a dry powder mixture of from about 1 % to about 10% (by weight)
polyvinylpyrrolidone, CaCl2 and combinations thereof.
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
The present invention provides for adding anti-infective properties to a solid
implantable device, comprising adding a formulation to the device wherein the
formulation comprises iodide, a means for releasing protons, and an oxidant.
Preferably,
the means for releasing protons is accomplished by hydrolysis of anhydrides or
through
an enzymatic reaction. Most preferably, the enzymatic reaction uses HZO2
generating
enzymatic oxidation of iodide, wherein the proton sources are supplied by a
body fluid
exposed to the device, or by wetting the device. The mechanism uses protons
generated
by the device to chemically convert iodide into elemental iodine, whereas the
absence of
water or body fluid exposure leaves the device in a dormant state.
In a fifth embodiment, the present invention provides a device for vaginal
insertion that provides infra-vaginal generation of anti-infective and
spermicidal
concentrations of iodine, which in one aspect of the invention involves a
mechanical-
release anti-infective and contraceptive device, comprising:
(a) a silicone walled tubing having walls defining a reservoir chamber,
wherein
the walls further comprise a plurality of self sealing holes extending through
the walls
and communicating with the reservoir chamber; and
(b) an aqueous formulation within the reservoir chamber, wherein the aqueous
formulation comprises iodide and an oxidizing means, wherein the iodide is
selected
from the group consisting of potassium iodide, sodium iodide, and combinations
thereof,
and wherein the oxidizing means is present in an amount sufficient to release
iodine from
the iodide upon expulsion of the fluid within the chamber to the external
medium and
subsequent mixing of the expelled fluid with protons, or substrate sources,
present in the
latter body fluid, and required for formation of elemental iodine.
Alternatively, the
substrates, proton source, iodide and oxidizing means may be formulated as a
dry
mixture to which water is added as a solvating agent immediately before use,
and which
then serves to solvate and initiate formation of anti-infective and
spermicidal iodine.
The dry mixture may be within the reservoir chamber, or may be separately
combined
with water and added to the reservoir chamber just prior to use.
Preferably, the oxidizing means is selected from the group consisting of
alkali
iodine oxide salts, peracids, Hz02-generating enzyme oxidases, and
combinations
thereof. Most preferably, the alkali iodine oxide salts are sodium iodate, or
iodine
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
21
pentoxide or both. Most preferably, the peracids are perborates, peracetates,
or both.
Most preferably, the Hz02 generating enzyme oxidases are selected from the
group
consisting of glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4)
or
diamine oxidase (amine:oxygen oxidoreductase[deaminating] [pyridoxal-
containing]; EC
1.4.3.6) and combinations thereof. Preferably, the H~02 generating enzyme
oxidases
optionally includes a peroxidase enzyme. Preferably, the peroxidase enzyme is
donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7.
Preferably, the aqueous formulation further comprises a viscosity augmentor.
Most preferably, the viscosity augmentor is a polycarboxylic or polyhydroxyl
complex
polymer selected from the group consisting of linear polyacrylates, cross-
linked
polyacrylates, hydroxyalkyl celluloses, polycarboxyalkyl celluloses, water
soluble
celluloses, polyethylene alcohols, vinyl alcohols, chitosan polymers, salts of
alginic acid,
and combinations thereof. Preferably, the viscosity augmentor is made up to
not less
than about 0.2% (by weight) in water, and not more than about 5% by weight in
water.
Most preferably, the viscosity augmentor is about 2% by weight of the aqueous
formulation. Preferably, the pH of the aqueous formulations is from about pH
3.0 to
about pH 6.5. Most preferably, the pH is about 4Ø
Preferably, the concentration of iodide in the aqueous formulation is from
about
0.1 mM to about 200 mM. Preferably, the oxidizing means is present in the
aqueous
formulation at a concentration from about 0.1 mM to about 200 mM when the
oxidizing
means is an alkali oxide of iodine or a peracid. Preferably, the oxidizing
means is
present in the aqueous formulation at a concentration from about 2 p.g/ml to
about 500
P.g/ml when the oxidizing means is a H2O2 generating enzyme oxidase.
Preferably, the
glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) is made up at
a
specific activity in the range of 2,000 to 200,000 IU per gram of solid, or
the diamine
oxidase (amine:oxygen oxidoreductase[deaminating] [pyridoxal-containing]; EC
1.4.3.6) is made up at a specific activity in the range of 50 to 800 IU per
gram of solid.
Preferably, the peroxidase (donor:hydrogen-peroxide oxidoreductase; EC
1.11.1.7)
enzyme is present at a concentration of from about 2 ~g/ml to about 500 p,g/ml
when its
specific activity is in the range of 250,000 to 330,000 IU per gram of solid.
Preferably, the device is formed into a circular shape suitable for vaginal
insertion
CA 02335055 2000-12-13
WO 99165538 _ PCT/US99113898
22
and retention in the cervical region. Suitable device circular shapes are
ring, concave
disc, and tampon. Preferably, the circular device has an outer diameter of
from about 3.0
cm to about 7.0 cm. Most preferably, the outer diameter is from about 5.6 cm
to about
6.0 cm. Preferably, the self sealing holes are from about 0.01 mm to about
0.15 mm in
diameter. Preferably, the self sealing holes are located about a circumference
of the
circular shaped device. Most preferably, the density of the self sealing holes
is from
about 1 to about 20 holes per cm2 of surface area.
In a sixth embodiment, the present invention provides a microcannular anti-
infective and contraceptive device, comprising a solid polymeric material
having small
channels contained therein and further comprising a dry iodine-generating
formulation,
wherein the device is formed into a circular shape suitable for vaginal
insertion and
retention in the cervical region, and wherein the dry iodine-generating
formulation is a
dry mixture of an iodine salt selected from the group consisting of anhydrous
potassium
iodide, anhydrous sodium iodide, and combinations thereof, and an oxidizing
agent,
wherein the oxidizing agent is selected from the group consisting of an
anhydrous alkali
iodine oxide salt, an inorganic or an organic peracid, a H202 generating
oxidase enzyme,
and combinations thereof.
Preferably, the concentration of anhydrous potassium iodide, anhydrous sodium
iodide, or both is from about 0.5% to about 16% (by weight) of the device.
Preferably,
the anhydrous alkali iodine salts are selected from the group consisting of
sodium iodate,
iodine pentoxide, and combinations thereof. Preferably, the inorganic or
organic
peracids are selected from the group consisting of perborates, organoperoxy
acids, and
combinations thereof. Most preferably the inorganic or organic peracids, if
the only
oxidizing agent present in the device, are provided at a concentration of from
about 0.5%
to about 16% (by weight) of the device. Preferably, the HZO2 generating
oxidase enzyme
is selected from the group consisting of glucose oxidase (D-glucose:oxygen 1-
oxidoreductase; EC 1.1.3.4), diamine oxidase (amine:oxygen
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6), and
combinations
thereof. Most preferably the H202 generating oxidase enzyme further comprises
a
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) enzyme.
Preferably,
the H20z generating oxidase enzyme, if the only oxidizing agent present in the
device, is
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
23
present at a concentration of from about 0.1% to about 2.5% (by weight) of the
device.
Most preferably, glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC
1.1.3.4) is
present at a concentration of at least 0.5% by weight of the device, wherein
the specific
activity of glucose oxidase is in the range of 2,000 to 200,000 IU per gram of
solid and a
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) is present at
a
concentration of at least 0.01 % by weight of the device, wherein the specific
activity of
peroxidase is in the range of 250,000 to 330,000 IU per gram of solid, with
the proviso
that the sum concentration of a combination of oxidase and peroxidase
(donor:hydrogen-
peroxide oxidoreductase; EC 1.11.1.7) enzymes is within the range of from
about 0.01
by weight to about 2.5% by weight of the device. Most preferably, diamine
oxidase
(amine:oxygen oxidoreductase[deaminatingJ (pyridoxal-containing]; EC 1.4.3.6)
is
present at a concentration of at least 0.01% by weight of the device, wherein
the specific
activity of diamine oxidase (amine:oxygen oxidoreductase[deaminatingJ
[pyridoxal-
containingJ; EC 1.4.3.6) is in the range of 50 to 800 IU per gram of solid,
and a
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) is present at
a
concentration of at least 0.01 % by weight of the device, wherein the specific
activity of
peroxidase is in the range of 250,000 to 330,000 IU per gram of solid, with
the proviso
that the concentration of the H202 generating oxidase enzyme is within the
range of from
about 0.01% to about 2.5% by weight of the device. Preferably, the
microcannular
device further comprises a desiccant to stabilize the iodine salts from
absorbing moisture
from the atmosphere and prematurely solvating and forming free iodine.
Preferably, a
desiccant is selected from the group consisting of a dry powder mixture of
from about
1% to about 10% polyvinylpyrrolidone, CaCl2 and combinations thereof.
Preferably, the
device is formed into a circular shape suitable for vaginal insertion and
retention in the
cervical region. Suitable device circular shapes are ring, concave disc, and
tampon.
Preferably, the device has an outer diameter of from about 3.0 cm to about 7.0
cm. Most
preferably, the outer diameter is from about 5.6 cm to about 6.0 cm.
Preferably, the solid
polymeric material is an elastomeric hydrophobic organosilicon.
Although discussed primarily in terms of elemental iodine producing
components, it should be understood that the various embodiments discussed
herein may
involve the use of alternative anti-infective oxidants, such as those
discussed above
CA 02335055 2000-12-13
WO 99!55538 PCT/US99/13898
2.1
which are produced in the body. These alternative anti-infective oxidants can
be
produced from precursor reactants encapsulated in a latent state within a
polymer base as
a delivery vehicle for the generation and release of the active agents with
introduction of
a third component essential for activation such as water as a solvating agent,
or a co-
factor essential for completion of the reaction in the generation of anti-
infective products.
Thus, for example, alternative oxidants which can be caused to form de novo on
demand
from precursor reactants include superoxide; hydrogen peroxide: hydroxyl
radicals;
hypohalites such as hypochlorite (OCI~, hypoiodite (OIL, and hypobromite (OBi
);
haloamines including chloramines, iodamines, and bromamines which are the
oxidizing
products formed through reaction of hypohalites with primary and secondary
amines
such as taurine chloramine formed by introduction of taurine to hypochlorite;
thiocyanogen ((SCN)2); hypothiocyanite (OSCN~; and nitric oxide.
Brief Description of the Drawings
Figure 1 shows that sodium iodide formulated at a mass ratio of solid to
silicone
elastomer of ~ 30% yields a polymeric base on curing which efficiently
releases iodide
upon immersion and sequential changes in buffer. Iodide peaked at around 50 to
60 mM
in a fluid volume of 10 ml buffer per washing interval. The capacity of the
fabricated
silicone device to restore iodide to this level with sequential changes in
buffer remained
relatively constant over the first 350 hrs, then declined to ~ 20 mM by around
600 hrs of
continuous immersion and rinsing. Calculations of iodide recovery, relative to
iodide
initially available in the device, indicated that by 600 hrs of continuous
immersion and
washing ~ 90% sodium iodide had leached free of the device.
Figure 2 shows the kinetic release of iodine pentoxide from silicone tablets
prepared as in the microbicidal studies summarized in Table 3, and suspended
in 100
mM sodium citrate, pH 4.0, at 1 tablebml, but using different mass ratios of
iodine
pentoxide to elastomer. The concentration of iodate released to buffer bathing
the tablet
can be seen to be proportional to the mass of iodine pentoxide encapsulated
within the
polymer base. Complex media had no apparent impact on solvation and diffusion
rates
of iodine pentoxide as identical rates of iodine pentoxide release were
observed in
substituting BHI media in place of citrate buffer.
CA 02335055 2000-12-13
WO 99/Cz5538 PC'TNS99/13898
Figure 3 shows the kinetic release of iodate and iodide at varying intervals
after
submersion of fabricated tablet formulated by mass with 8% iodate, 2% iodide
and 10%
PVP, an optimal formulation found effective in killing C. albicans when added
to BHI at
1 tablet/ml. Tablets were submerged at room temperature in 100 mM sodium
citrate, pH
4.0, and aliquots of the buffer then drawn for analysis of iodate and iodide
at the intervals
indicated. Peak levels of iodate and iodide in the range of 2 and 1 mM,
respectively,
proved sufficient to catalyze formation of sufficient elemental iodine in the
external
media to kill C. albicans completely in less than 4 hours exposure to the
tablets.
Figure 4 shows corresponding elemental iodine levels formed in the external
medium (100 mM sodium citrate, pH 4.0) at varying intervals of submersion of
fabricated silicone tablets ( 1 tablet/ml) formulated as in examples 3 and 4
at 8% iodate,
2% iodide and 10% PVP by mass relative to the silicone elastomer.
Figure 5 shows elemental iodine formed de novo with solvation of a 1 % high
viscosity alginate hydrogel device formulated in 2 mM potassium iodide, 2 mM
sodium
iodate prior to lyophilization. The lyophilized hydrogel was submerged as a 1
cm x 0.6
cm cylindrical section in 1 ml of 100 mM sodium citrate, pH 4.0, and allowed
to solvate
for 20 minutes before measuring elemental iodine in the buffer medium. Values
represent the average of triplicate experiments. The control experiment showed
the
absence of elemental iodine in sample processed in the same manner, but
excluding
potassium iodide and sodium iodate from the hydrogel matrix during preparation
of the
control device.
Figure 6 shows proton driven de novo formation of nascent elemental iodine and
demonstrates comparable rates of elemental iodine formation at pH 4.5 versus
pH 7.4
using fixed concentrations of horseradish peroxidase, iodide and glucose, and
variable
levels of glucose oxidase, as indicated.
Figure 7 shows the release of iodate and iodide from silicone and polyethylene
coated cannular tubing. The coatings were formulated in 2.5 and 5.0 cm lengths
of
silicone polymer layered over the cannulae and encapsulated with iodate and
iodide made
up in PVP (as described in example 6) and with a wall thickness of ~ 0.1 mm.
The
polymer-coated cannulae were then immersed in 5 ml of 100 mM citrate buffer,
pH 4.0,
and aliquots of the buffer solution than periodically analyzed for residual
iodate and
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
26
iodide as indicated over a period of approximately 28 hours. Elemental iodine
formed in
the wash buffer was also assayed and found to range from a low of ~ 4 ppm to a
high of
~30 ppm over this same interval. Peak levels of iodide and iodate occurred at
about 24
hours after submersion of the coated cannulae in the citrate buffer.
Figure 8 shows two configurations of the inventive mechanical=release device
in
an unfolded (left) and ring (doughnut) configuration (right) for insertion
into the vagina
against the cervix.
Figure 9 shows the activity of the spermicidal formulation in immobilizing
human sperm. In these experiments glucose oxidase was set at 416 ug/ml,
horseradish
peroxidase was at 17 ug/ml, iodide was held constant at 63 mM, and glucose was
11.6
mM. Semen was diluted 6-fold in isotonic saline made up in 10 mM sodium
phosphate
buffer, pH 7.4, and sperm motility scored within 20 seconds of mixing semen
with the
test reactants. Washing sperm free of the formulation failed to restore sperm
motility
indicating irreversible immobilization of the sperm. Omission of iodide, or
either
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) or glucose
oxidase
(D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4), from human semen samples
resulted
in retention of sperm motility. Assays of sperm mobility were based upon WHO
standards using the modified Sander-Cramer sperm motility assay. Error bars
indicate ~
1 SD of duplicate determinations of a single donor. Comparable results were
obtained on
six separate donor specimens obtained on samples of four individual sperm
donors. All
sperm samples tested met all standard characteristics for assessment of sperm
motility (>
20 x 106 sperm/ml, > 50% motility and > 50% normal forms).
Figure 10 illustrates a transverse cross-sectional view of a catheter which
embodies features of the invention, having a catheter shaft formed of a
polymeric matrix
containing an oxidant producing component throughout the shaft.
Figure i 1 illustrates a transverse cross-sectional view of a catheter which
embodies features of the invention, having a catheter shaft having a body and
a layer of a
polymeric matrix containing an oxidant producing component in the polymeric
matrix.
Figure 12 illustrates a longitudinal cross-sectional view of a glove which
embodies features of the invention, formed of a polymeric matrix containing an
oxidant
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
27
producing component and having a proton source dusted onto an inner surface of
the
glove.
Detailed Description of the Invention
The present invention provides a medical device having microbicidal,
virucidal,
and spermicidal activities. In accordance with the invention, the medical
devices are an
implantable or topical (wound) devices that exhibit microbicidal and virucidal
activities
through their capacity to generate an oxidant such as elemental iodine over
sustained
intervals, activated upon submersion of the devices in aqueous fluids. Unlike
antibiotic
strategies, the incorporation of iodine generating formulations into the
devices fabricated
out of hydrophobic and/or hydrophilic polymers circumventes the problem of
colonizing
antibiotic resistant organisms, lending better care and less risk to users of
the inventive
device for both the prevention and treatment of infections. Although discussed
below
primarily in terms of elemental iodine as the anti-infective, spermicidal
oxidant
generated by the medical devices of the invention, it should be understood
that other
oxidants may similarly be used, as outlined herein.
The inventive process mixes finely ground particles of the oxidant producing
compound, such as iodine salts, directly into the polymer base prior to its
curing and/or
fabrication, as a coating, or as a device, of specific dimensions and
configuration. These
salts remain inert and trapped within the polymer base until they come into
contact with
body fluids. The salt mixtures within the microcannulae react with one another
upon
solvation catalyzing the formation of elemental iodine. A steady supply of
nascent
elemental iodine was generated over a period of several hours, several days,
or weeks
depending upon the chemical properties of the polymer base in which the salts
were
encapsulated, the concentration of salts and reactants relative to the mass of
the polymer,
and the reactants making up the salt mixture. The inventive device aims to
produce an
optimal microbicidal killing level of from about S to 100 ppm of elemental
iodine.
Either hydrophilic (water soluble) or hydrophobic (water insoluble) polymer
bases can be
used in fabricating the inventive device. Anti-infective properties may be
conferred to
implant devices by coating of prefabricated devices with a layer of
hydrophobic or
hydrophilic polymers encapsulating elemental iodine generating formulations,
or the
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
28
entire device may be fabricated from polymers encapsulating elemental iodine
generating
formulations.
The following principles apply in fabricating the inventive device. First,
elemental iodine generating formulations must be entrapped in the form of
solids within
the polymer base in a dormant state until solvated. Second, formation of
nascent
elemental iodine must occur rapidly, facilitated by maintenance of high
concentrations of
iodine salts at the solvation site by exploiting oxidation and conversion of
iodide into
elemental iodine, and by providing a supply of protons within the reaction
environment.
The inventive devices (implantable, vaginal treatment and wound dressing) each
involve fabrication of anti-infective activity using polymers molded to a
specific shape,
dependent upon the application required of the device. In incorporating the
inventive
device into urinary catheters and various other body implant devices, the
device prevents
acquisition of infections by conferring to the devices in which it is
incorporated the
capacity to cleanse the site of implantation of pathogenic microbes and
viruses. Devices
encapsulating various elemental iodine generating formulations can be
fabricated for the
treatment of acquired infections such as BV, or pPROM, wherein the fabricated
device
may be configured and placed within the vagina, or against the cervix, to
treat such
infections. The same device can be fabricated for use as a coating on
preformed devices
(e.g., orthopedic joints, metal inserts, cardiac pacemakers, etc.), or
prepared in the shape
of a sheet or "bandaid" as a wound dressing, protecting wounds and burns from
infection.
The present invention is based upon the discovery that dry oxidized and
reduced
salts of iodine can be trapped in hydrophilic and hydrophobic polymers in
stable form.
When exposed to fluids present in body cavities, such as the vagina, urethra,
or in
interstitial spaces, the dry oxidized and reduced salts of iodine solvate, and
react to form
free microbicidal and virucidal elemental iodine. Osmotic gradients
established within
the device's polymer base, in combination with solvation of the iodine salts
and
oxidative reactions, account for the sustained formation of nascent elemental
iodine. The
invention also utilizes natural reducing compounds present in biological
fluids (such as
in the vagina and other body cavities) for enhancing nascent elemental iodine
formation.
This is accomplished with chemical forms of iodine encapsulated within the
device
which are susceptible to reduction, and which can then be caused to oxidize,
either
CA 02335055 2000-12-13
WO 99/45538 PCTNS99/13898
?9
nonenzymatically or enzymatically, into nascent elemental iodine.
Hydrophobic silicone polymers encapsulated with iodine salts and its oxides
have
been fabricated into devices with anti-infective activities. Similar
embodiments of the
device have been developed using the hydrogels, alginic acid, and
polyacrylates, which
in fabricated forms can be inserted into various body cavities, or over
wounds, where
they confer to the treated site microbicidal and virucidal activities.
With reference to the Figures. Figure I shows the capacity of a 5 g block of
silicone to release encapsulated sodium iodide. The device was fashioned in
the shape of
a disc ~ 0.3 cm thick and 5.0 cm in diameter and sodium iodide was embedded in
the
hydrophobic elastomer prior to curing. The disk was immersed in an aqueous
fluid
comprised of 10 mM sodium phosphate, pH 7.4, also made up in 150 mM NaCI. The
data in Figure 1 show the release of sodium iodide over a period of
approximately one
month.
Figure 2 shows that an anhydride of iodate, iodine pentoxide, can likewise be
entrapped in microcannulae formed during curing of silicone disc devices
fabricated in
the same manner as in Figure 1, but substituting the anhydride in place of
iodide. The
concentration of the oxide salt released into solution was proportionate to
the amount of
oxide encapsulated within the silicone polymer prior to curing and fabrication
of the
device.
Figure 3 shows that both iodate and iodide may be encapsulated simultaneously
within the silicone polymer base during fabrication of a silicone disc device
as in Figure
1. Upon solvation, iodate and iodide react in coming together to form nascent
elemental
iodine. The presence of elemental iodine was confirmed in the immersion buffer
(see
Figure 4), and devices fabricated in this manner were also shown to exhibit
potent
microbicidal activities (see examples 3 and 4).
Figure 4 shows corresponding elemental iodine levels formed in the external
medium ( 100 mM sodium citrate, pH 4.0) at varying intervals of submersion of
fabricated silicone tablets ( 1 tablet/ml) formulated as in examples 3 and 4
at 8% iodate,
2% iodide and 10% PVP by mass relative to the silicone elastomer.
Figure S shows the release of elemental iodine into immersion buffer ( I 00 mM
sodium citrate, pH 4.0) from a hydrogel polymer embodiment. The hydrogel
polymer
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
was composed of 1% high viscosity alginic acid and fabricated in the shape of
a cylinder
suitable for insertion into a wound incision (see example 5). Iodide and
iodate was
encapsulated within the lyophilized alginic acid polymer. The hydrogel device
was
activated upon placement of the device in aqueous fluid (i. e., immersion
buffer). Upon
immersion, the hydrogel solvated and dissipated into the buf~ersolution so
that it was not
necessary to remove the device from the site of treatment.
Figure 6 shows proton driven de rrovo formation of nascent elemental iodine
and
demonstrates comparable rates of elemental iodine formation at pH 4.5 versus
pH 7.4
using fixed concentrations of horseradish peroxidase (donor:hydrogen-peroxide
oxidoreductase; EC 1.11.1.7), iodide and glucose, and variable levels of
glucose oxidase
(D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4), as indicated.
Figure 7 shows the time dependent release of iodide and iodate from strips of
polyethylene and silicone cannulae coated with thin layers of silicone polymer
encapsulated with an elemental iodine generating formulation comprised of
iodide,
iodate and PVP (see example 7). The inventive device prototype was submerged
in 100
mM sodium citrate buffer, pH 4Ø The average level of nascent elemental
iodine formed
over the duration of the immersion intervals as a result of the release of
iodide and iodate
ranged from a low of 4 ppm to a high of 30 ppm.
Fabrication of the Inventive Device
The inventive device contains a reservoir containing an iodine generating
formulation designed to produce iodine, when activated, in the range of about
5 to 100
ppm. The inventive device relies upon the presence of specific reducing
compounds
and/or substrate compounds found in body fluids as "activating agents."
Substances
present in body fluids and which activate iodine formation from the inventive
formulation include reducing compounds such as ascorbic acid, glutathione, and
hypotaurine, and substrate compounds such as glucose, and spermine, and water
as a
solvating agent. The substrate compounds are often coupled with H202
generating
oxidase-type enzymes, such as glucose oxidase (D-glucose:oxygen 1-
oxidoreductase; EC
1.1.3.4) or diamine oxidase (amine:oxygen oxidoreductase[deaminating)
[pyridoxal-
containing); EC. I .4.3.6), for example, and facilitated by a peroxidase
(donor:hydrogen-
peroxide oxidoreductase; EC 1.11.1.7) such as horseradish peroxidase or
lactoperoxidase
CA 02335055 2000-12-13
WO 99/b5538 PCTNS99/13898
31
formulated as a dry powder mixture. This dry powder mixture is encapsulated
within the
polymer base of the inventive device during fabrication. Upon solvation, the
oxidase
enzymes come into contact with their respective substrates, thereby triggering
formation
of HZOZ. The H202 formed as a product of the oxidases acting on their
substrate
compounds then serves to oxidize iodide (also included in the formulation)
into iodine
conferring to the device anti-infective (e.g., microbicidal and virucidal),
and
contraceptive spermicidal, activities. Dry, finely ground oxides of iodine
salts, peracids,
or comparable oxidizing agents (e.g., perborate, peracetate, etc.) can be
substituted in
place of the oxidase enzymes in formulations entrapped within the inventive
device.
In the oxidative conversion of iodide into iodine, a wide array of oxidants,
i.e.,
oxidizing agents, may be employed so long as they can be formulated into an
anhydrous
powder. Thus, the oxidants remain immiscible upon addition to the hydrophobic
polymer used in fabricating the delivery device, and they retain the capacity
to solvate
upon immersion in aqueous fluids so that they can come into contact with
iodide, and
thereby cause its conversion to iodine. In this case of sodium iodate, or
iodine pentoxide
(which spontaneously hydrolyzes to iodate), crystalline salts become entrapped
in
microcannulae of the delivery device and egress from the device upon coming
into
contact with body fluid such as vaginal fluid. The crystalline salts react
with reducing
compounds present in the vaginal fluids and semen, resulting in elemental
iodine
formation in accordance with redox reactions involving iodine chemistry.
Hence, the use
of iodate in formulations exploits the reducing environment in which the
device resides
to allow for elemental iodine formation to ensue, bathing the vaginal walls
and cervix in
spermicidal and microbicidal iodine activity (e.g., from 5 to 100 ppm).
For incorporation of formulations into hydrophobic polymers, fabrication of
the
inventive device requires that the iodine-generating formulation first is
ground to a fme
powder of 200 micron, or less. The dry formulation is then mechanically mixed
at room
temperature (20 to 25° C) into a hydrophobic elastomer used as the
polymer base in
fabricating the device to form a mixture. Variations in producing master
batches prior to
curing in the final polymer base are amenable to the technology. For example,
the anti-
infective oxidant generating component such as potassium iodide, may be
premixed in
one co-polymer (Part A). The proton source such as monosodium phosphate and an
CA 02335055 2000-12-13
WO 99/b5538 PCT/US99/13898
32
oxidizing agent such as sodium iodate can then be mixed into the other co-
polymer
crosslinking agent together with an appropriate catalyst (Part B). To cure the
polymer,
Part A and Part B may then be mixed together allowing for initiation of the
crosslinking
polymerization process concomitant with encapsulation of the iodine-generating
formulation within the final mixture. Before the mixture has cured, the
mixture may then
be delivered to a mold, or extruded from a dye, and allowed to cure to its
final
configuration. The shape of the device is suitable for its site of
application. Suitable
configurations include extruded sheets to be layered over wounds and buns for
the
prevention and treatment of surface infections, formation of rings and tampons
for the
treatment and/or prevention of vaginal infections, or pPROM, fabrication in
the shape of
a Foley catheter for the prevention of urinary tract infections and formation
of a self
sterilizing urinary catheter, extrusion as a covering over a catheter lead
wire in conferring
to the latter anti-infective properties, etc. The intended use in a particular
body cavity or
wound site determines the appropriate shape.
Suitable hydrophobic polymers (elastomers) to be used in fabrication of the
inventive device include, for example, medical grade Low Consistency Silicone
elasotmers (LSR silicone elastomers) such as NuSil MED-4815, -4820, -4830, -
4840 or -
4850 molding materials, NuSil medical grade LSR4-5805 silicone elastomer, High
Consistency Silicone Elastomers (HTR elastomers) suitable for extrusion such
as NuSil
MED-4550, -4565, -4719, --4750 and -4780, as well as thermoplastic. and room
temperature vulcanization silicone polymers. Other suitable polymers include
elastomers
such as polyurea, polyurethane, ethylene vinyl acetate, polyvinylchloride,
polyesters,
polyamides, polycarbonate, polyethylene, polymethyl methacrylate, cellulose
esters such
as ethyl, methyl and propyl forms, polypropylene, polystyrene,
polytetrafluoroethylene,
poly(ethylenevinyl acetate), eiastomeric organosilicon polymers, poly(hydroxyl
alkyl
esters), copolymers and thermoplastic hydrophobic combinations thereof.
For formulations encapsulating enzymes such as glucose oxidase (D-
glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) or diamine oxidase (amine:oxygen
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6), room
temperature
vulcanization elastomers must be used in fabricating the device from
hydrophobic
polymers since enzymes will denature using the higher temperatures required in
curing
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
33
thermoplastic polymers. The higher curing temperatures, in the range of from
120 to 170
°C, pose no problem for entrapment of nonenzymatic components of the
formulations
used in fabricating this device. The free level of iodine formed at the
surface of the
device upon wetting the device in body fluid should preferably reach a level
not less than
~S ppm, or in excess of 100 ppm within 20 minutes of its exposure to body
fluid. This
level of elemental iodine is highly desirable to confer to the device
microbial, virucidal
and spermicidal activities.
Alternatively, the inventive device may be fabricated from a hydrophilic
(e.g.,
hydrogel) polymer. In this embodiment, the polymer base serves to encapsulate
the
iodine generating formulation and solvates concomitantly with activation of
the iodine
generating formulation as a gel-sol, mucoid-like product, coating and bathing
the implant
site with anti-infective activity.
Suitable hydrogels for mixing into formulations include, for example, from
about
0.2 to S % high or medium viscosity alginic acid, B.F. Goodrich Carbopol 971
PNF (or
crosslinked analogues of this polyacrylic acid such as B.F. Goodrich Carbopol
974 PNF
or Noveon''''~' AA1 ), or about 1:1 mixtures of aiginic acid and Carbopol,
adjusted from to
a preferred pH of about 3.7 to 4.2 with NaOH. Several classes of hydrogels are
amenable
to this embodiment, in general, including hydrogels selected from groups
consisting of
linear or cross-linked polyacrylates, polycarboxyalkyl celluloses,
hydroxyalkyl
celluloses, water soluble celluloses, polyethylene or polyvinyl alcohols,
chitosan
polymers, as well as salts of alginic acids and combinations thereof.
Providing for a low pH in the hydrogel embodiment of the device is important
in
ensuring a steady supply of H+ in forming elemental iodine (see example 6).
Additionally, in the embodiment in which the device is used intravaginally,
the low pH
of the hydrogel is important in maintaining the pH of the vaginal fluid at its
normal pH
(e.g., ranging from about 3.7 to 4.5). The low pH has an additional advantage
in that it
also confers some spermicidal and microbicidal activity to the hydrogel
formulation. The
hydrophilic polymers (e.g., hydrogels) containing the elemental iodine
generating
formulations must first be premixed at low temperatures near the freezing
point of water.
They can then be transferred to a mold, and frozen and lyophilized to remove
water,
forming an anhydrous, stable formulation, preferably in the shape of a disc,
that can be
CA 02335055 2000-12-13
WO 99/45538 PCT/US99/13898
34
manually inserted into the vagina against the base of the cervix. This process
of freezing
and then lyophilizing the formulation yields a sponge-like product capable of
producing
microbicidal and virucidal levels of nascent elemental iodine upon
introduction to body
fluids. Upon insertion into the vagina, the disc solvates to a thick gel,
adhering tightly to
the vaginal and cervical epithelium with the consistency of a thick mucous-
like
substance, releasing the active ingredients by which elemental iodine can then
be formed.
The anhydrous, stable formulation can be stored in desiccated form without
loss of
iodine generating activity.
Iodide and oxidizing agents of iodide such as iodate salts, or enzyme oxidases
such as glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) and
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7), may be mixed
together and formulated into a single hydrogel formulation, or the iodide and
oxidizing
agents may be cast in separate hydrogel formulations, and, once recovered in
lyophilized
form, reassembled as a bilayer of iodide and oxidizing agent.
The freeze-drying technique for fabrication of the hydrogel embodiment of the
inventive device allows for fabrication of a dissolvable, anti-infective,
spermicidal,
hydrogel formulation. The sponge-like hydrogel product can be pressed into
sheets, or
rolls, and cut into various shapes, by placing the lyophilized hydrogel
product in a
hydraulic press and applying a pressure of not less than 100 lbs per square
inch, nor more
than 12,000 lbs per square inch to the final product. This yields a fine,
paper-like
product which can be cut and shaped as desired, and which upon wetting
rehydrates to a
gel solution.
A hydrogel device is formed into varying shapes (sheets) for application to an
infected site by layering one hydrogel sponge product containing iodide on top
of a
second containing the oxidizing agent required to trigger formation of
elemental iodine
to form a composite sandwich product, placing the composite sandwich product
into a
hydraulic press, and then applying pressure to the two layers stacked one on
top of the
other to form a bilayer membrane. The wetting of the latter sandwich product
results in
solvation of the hydrogel sandwich, and concomitant production of anti-
infective iodine.
In another embodiment, a mechanical-release device is provided which releases
oxidant generating formulations, such as iodine generating formulations,
contained
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
within an interior reservoir of the device. Operation of the mechanical-
release device
involves addition of iodide and/or its oxides, with or without reducing
substrates,
substrate compounds, inorganic or organic oxidizing agents. or H2O2 generating
enzymes
within an interior chamber defined, for example, by silastic (silicone)
tubing. Preferably,
the silastic tubing is formed as a ring shape so that it may be seated at the
fornix between
the cervix and vaginal wail (Figure 8). Preferably, the diameter of the outer
ring is from
about 5.8 to about 6.2 cm. Preferably, the tubing is perforated with a series
of self
sealing holes of approximately 0.01 to 0.1 mm diameter, dispersed relatively
uniformly
about the circumference of the tubing (that is toward to outside, as opposed
to the inside,
of the ring-like structure) at a density of from about 1 to about 20 holes per
cm2. The
holes allow for release of the iodine generating formulation only during
compression and
distortion of the tubing through flexing, stretching and rotational motion
occurring
during sexual intercourse as a result of spontaneous muscular contractions
initiated at the
base of the cervix during arousal and intercourse. The holes in the tubing are
sufficiently
small so that the "elastic memory" of the silastic tubing seals formulation
within the
inner reservoir of the device when the tubing is in a relaxed, or in an
undistorted state,
retaining the contents held within the inner core reservoir (e.g., the lumen
of the tube),
preventing mixing of elemental iodine generating formulation within the inner
reservoir
from presentation to the vaginal walls and cervix in the vicinity of the
cervical os. Thus,
only during vigorous distortion of the ring through muscular contractions (as
occurs
during sexual arousal and intercourse) can the iodine generating formulation
contained
within the interior chamber of the tubing egress, or "weep", to the external
surface of the
delivery device. Upon contact with the external surface of the device, the
formulation
provides, essentially, an "on demand" formation of iodine. Moreover, once
outside the
inner reservoir, the formulation responsible in generating elemental iodine
can be caused
to smear across and coat the cervix and vaginal wails during intercourse,
thereby creating
a chemical barrier across which bacteria, viruses and sperm cannot penetrate.
Thus, the
source of elemental iodine in a preferred embodiment is presented only "on
demand"
during sexual arousal and intercourse. By devising the delivery system so that
it can be
caused to activate at the time of sexual arousal and intercourse, appropriate
concentrations of elemental iodine, in the range of 5 to 100 ppm, for both
spermicidal
CA 02335055 2000-12-13
WO 99/b5538 PCT/US99/13898
36
and anti-infective activities, can be formed locally at the time they are
needed. The user
does not need to time intercourse closely with application of the
contraceptive agent. In
addition, by the design of "on demand" delivery of elemental iodine, the
effectiveness of
this birth control method is enhanced because it does not call upon the
attention of the
user to time and carefully orchestrate use of the device in order for it to
work effectively
at the time of sexual arousal and intercourse.
During the manufacture of the mechanical "on demand" release device, the
silastic tubing is produced in an elongated configuration in which two holes
(having a
diameter of from about 0.20 to about 0.25 cm) are placed adjacent to one
another, from
0.3 to 0.4 cm distance apart, in a straight line from one another along the
longitudinal
axis of the tubing, and located on a sleeve fabricated into the tubing (Figure
8). One hole
serves as an air vent for allowing air to escape the reservoir during loading
of the device
with the iodine generating formulations. The other serves as the inlet hole by
which the
formulations are delivered into the inner reservoir of the tubing.
To load the device, the end of the tubing containing the sleeve is inserted
into the
opposite open end of the tubing, leaving the air and vent holes exposed, and
bringing the
device into the shape of a ring (Figure 8). The formulation to be placed in
the device is
then delivered by means of a tapered "eye dropper" dispensing bottle designed
so that the
pointed dispensing end fits into the inlet hole. Eye droppers, or any cone
shaped
pipetting tip small enough to pass into the delivery inlet hole will suffice
in loading
formulations into the device. Formulations for generating elemental iodine are
loaded
through the inlet hole while holding the ring in a position so that fluid will
not spill out
the vent hole as the reservoir is loaded. Fluid can be loaded into the ring
until the last air
bubble appears at the air vent hole. At this point, the ends of the tubing
joined to one
another through the sleeve fitting are pushed tightly together causing the
opposite end of
the tube lacking the sleeve to slide over the inlet and air vent holes, thus
closing off any
possibility of fluid escaping back out of the inlet loading and air vent
holes, and forming
a tightly sealed delivery device (Figure 8) ready to be placed manually at the
base of the
cervix such that it surrounds the cervix and sits snugly between the fornix
and vaginal
wall.
CA 02335055 2000-12-13
WO 99/65538 PGT/US99/13898
37
In the fully closed ring configuration, formulations loaded into the device
necessary in catalyzing formation of elemental iodine can no longer escape
except
through the small "weep" holes distributed about the circumference of the
tubing. These
weep holes are self sealing in the same fashion as a serum septum cap retains
self sealing
properties after being punctured by a 20 to 21 gauge needle, yet they allow
the
formulation loaded into the device to "weep" out as the tubing is stretched
and distorted.
It is important that the diameter of the "weep" holes not be too large to
render the silastic
tubing leaky, resulting in the loss of formulation before the device can be
properly
inserted into the vagina, and at inappropriate times outside periods of sexual
arousal and
intercourse. While the above description focuses on a tube-type chamber, other
configurations are also applicable wherein the basic elements of the
mechanical release
device entail a flexible, self sealing wall, and inner hollow, from which
iodine generating
formulations may be caused to "weep" through distortions in the walls of the
device
caused during sexual arousal and muscular contractions occurring during sexual
intercourse.
Formulations.
In both the mechanical-release and the hydrogel delivery device, similar
iodine
generating formulations are used. In both instances the formulations are
prepared in a
lyophilized, anhydrous state containing a hydrogel to provide body (viscosity)
to the
formulation, and to render it stable for storage until required for use. In
the case of the
mechanical-release device embodiment, the formulation is, in principle,
hydrated by the
addition of a defined quantity of water before use to bring the ingredients to
their stated
concentrations made up prior to IyophiIization of the formulation. It is
feasible to
prepare the lyophilized formulation so that it is inserted within the
mechanical-release
device such that water is the only ingredient required in reconstituting the
formulation
through addition to the mechanical-release device, added through the loading
port hole
(Figure 8). Alternatively, the formulation can be prepared in a lyophilized
form within a
separate loading container, such as a plastic bottle with a tapered tip. The
tapered tip is
preferred for loading its reconstituted formulation contents into the delivery
device. On
the other hand, the hydrogel delivery device is preferably fonmed in a
lyophilized state
for direct insertion into the vagina and relies upon body fluids for solvation
and release
CA 02335055 2000-12-13
WO 99/65538 PCT/US99I13898
38
of the iodine generating formulation. Hence, it requires no addition of water
or other
aqueous solvent to reconstitute it before its insertion and use within the
vagina.
Reconstituted aqueous formulations are comprised of iodide, wherein the iodide
is selected from the group of potassium iodide, sodium iodide and combinations
thereof,
an oxidizing agent, wherein the oxidizing agent is selected from the group
consisting of
alkali iodine oxide salts such as sodium iodate, iodine pentoxide, other
inorganic or
organic oxidizing agents, peracids (e.g., perborate, peracetate, etc.), and
combinations
thereof. Alternatively, the oxidizing agent is replaced by H202 generating
enzyme
oxidases, such as glucose oxidase (~-D-glucose:oxygen 1-oxidoreductase; EC
1.1.3.4) or
diamine oxidase (amine:oxygen oxidoreductase[deaminating] [pyridoxal-
containing]; EC
1.4.3.6), facilitated by the addition of peroxidase (donor:hydrogen-peroxide
oxidoreductase; EC 1.11.1.7), and combinations thereof. The concentration of
iodide in
the aqueous formulations should be not less than about 0. I mM or more than
about 200
mM. The oxidizing agent acting on iodide may be chosen from alkali oxides of
iodine
such as sodium iodate, or iodine pentoxide, or peracids made up in solution
prior to
lyophilization and reconstitution to not less than 0.1 mM nor more than 200
mM.
Alternatively, H202 generating enzyme oxidases may be substituted in place of
the inorganic or organic oxidizing agents. Glucose oxidase, for example, may
be made
up in solution prior to lyophilization at a concentration of at least 2 p.g/ml
wherein its
specific activity is in the range of 2,000 to 200,000 IU per gram of solid.
Peroxidase
may be incorporated into the formulation to facilitate the oxidative
conversion of iodide
to iodine made up at a concentration of at least 2 pg/ml, wherein its specific
activity is in
the range of 250,000 to 330,000 IU per gram of solid, or diamine oxidase
(amine:oxygen
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6) may be
substituted in
place of glucose oxidase made up to at least 2 ~g/ml wherein its specific
activity is in the
range of 50 to 800 IU per gram of solid, or any combination thereof.
In addition to these reactive ingredients, the formulations are optionally
supplemented with a hydrogel agent, wherein the hydrogel agent is selected
from the
group consisting of linear polyacrylates, cross-linked polyacrylates,
polycarboxyalkyl
celluloses, polyalkyl celluloses, hydroxyalkyl celluloses, water soluble
celluloses,
polyethylene or vinyl alcohols, chitosan polymers, salts of alginic acids, and
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
39
combinations thereof. The hydrogel is preferably made up to not less than
about 0.2%
(by weight) in water, nor more than about 5% by weight. Preferably, the
hydrogel is
about 2% by weight of the composition. Preferably, the pH is adjusted to a
range of not
less than about 2.0 and not greater than about 6.5. Most preferably, the pH is
about 4Ø
Examples of specific hydrogels suitable for use include cross-linked
polyacrylates, such
as Polycarbopol 974 PNF or Noveon TM AA1 (B. F. Goodrich), crab shell
solubilized
chitosan (poly-[1--~4]-[i-d-glucosamine), carboxyethyl- and methyl cellulose
polymers,
and sodium salts of alginic acid (ranging from high to medium viscosity - 2%
solution at
25 °C equivalent ranging from 14,000 cps to 3,500 cps, respectively).
In fabricating the inventive device from hydrophobic polymers, the same basic
iodine generating formulations used in hydrogel delivery devices, excluding
hydrogels in
the final formulations, and water (aqueous solvent or salts thereof), can be
used.
Formulations are mixed and slurried into hydrophobic polymers used in
fabricating the
device in the form of anhydrous powders, ground to less than 200 microns,
which after
mixing and curing, form microcannula within the fabricated device from which
the
ingredients can then react upon solvation with exposure of the device to body
fluids.
Suitable hydrophobic elastomers for encapsulation of the iodine generating
formulations
include polyurea, polyurethane, ethylene vinyl acetate, polyvinylchloride,
polyesters,
polyamides, polycarbonate, polyethylene, polymethyl methacrylate, cellulose
esters such
as ethyl, methyl and propyl forms, polypropylene, polystyrene,
polytetrafluoroethylene,
poly(ethylenevinyl acetate), elastomeric organosilicon polymers, poly(hydroxyl
alkyl
esters), copolymers and thermoplastic hydrophobic combinations thereof,
wherein the
dry iodine-generating component is a dry mixture of an iodine salt selected
from the
group consisting of anhydrous alkali iodine salts such as potassium or sodium
iodide at a
concentration of from about 0.01 % to about 16% (by weight}, and an oxidizing
agent,
wherein the oxidizing agent is selected from the group consisting of anhydrous
alkali
iodine oxide salts such as sodium iodate, or iodine pentoxide, or a peracid or
its salt, such
as perborate, organoperoxy acids, and the like, at a concentration of from
about 0.01 % to
about 16% (by weight). Alternatively, a H~02 generating enzyme oxidases may be
used,
such as glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) or
diamine
oxidase (amine:oxygen oxidoreductase[deaminating] [pyridoxal-containing]; EC
CA 02335055 2000-12-13
WO 99/_65538 PCT/US99/13898
1.4.3.6), and facilitated by peroxidase (donor:hydrogen-peroxide
oxidoreductase; EC
1.11.1.7), and combinations thereof at a concentration of from about 0.01 % to
about
1.5% (by weight), whereby with solvation of the dry mixture and egress from
the device,
iodine is formed.
Polyvinylpyrrolidone, CaCl2, or other desiccants may be added to the
formulations to improve the stability of the encapsulated formulations. The
iodine
oxides, in combination with iodide, are hydroscopic and can draw moisture from
the
atmosphere into the microcannulae of the device leading to premature release
of iodine
generating activity. From 1 % to 10% powdered polyvinyipyrrolidone by
elastomer
weight, or a comparable amount of an alternate crystalline desiccant, such as
CaCl2,
included in the formulation, alleviates premature release of elemental iodine
from the
fabricated device.
In the inventive device, specific reducing compounds or substrate compounds
present in biological fluids can be exploited in promoting the formation of
nascent
elemental iodine through the design of the elemental iodine generating
formulations
entrapped within the microcannula of the (hydrophobic) polymer base.
Substances in
vaginal fluids, for example, and which can be used to enhance nascent
elemental iodine
formation, include reducing compounds such as ascorbic acid, glutathione, and
hypotaurine, and the substrate compound glucose.
A substrate compound (such as glucose) coupled with an oxidase-type enzyme
(e.g., glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) when
glucose is
a substrate), and a peroxidase (donor:hydrogen-peroxide oxidoreductase; EC
1.11.1.7)
(such as horseradish peroxidase) is formulated as a dry mixture. The dry
mixture is
encapsulated within a hydrophobic polymer base along with iodide. Such a
formulation
illustrates exploitation of reducing equivalents present in body fluids as a
source of
generating nascent elemental iodine. Upon solvation, the oxidase and
peroxidase
enzymes in the formulation come into contact with glucose (from a biological
fluid),
triggering formation of hydrogen peroxide (H202) as a product of glucose
oxidase acting
on glucose. H20z serves as a substrate in combination with iodide anion (also
included
in the formulation) to convert iodide into nascent elemental iodine via
peroxidation by
horseradish peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7).
The
CA 02335055 2000-12-13
WO 99/55538 PCT/US99/13898
41
same formulation can be used for devices fabricated out of hydrogels coming
into contact
with whole blood, serum or serum transudates, and various other body fluids,
where
glucose can be found in abundance and harnessed through the glucose oxidase
and
horseradish peroxidase reaction to catalyze nascent formation of elemental
iodine.
It should be noted that the glucose oxidase/horseradish peroxidase elemental
iodine generating formulation confers substrate (i. e., glucose) specificity
to the inventive
device. In the absence of glucose (such as when the device is stored) in the
polymer
formulation the formulation cannot catalyze formation of nascent elemental
iodine
because glucose is an essential first step component of the chemical reactions
leading to
elemental iodine formation. This particular formulation allows for the device
to activate
and lay down anti-infective activity only upon contact with body fluids
containing
glucose. Even exposure to water does not active the release of iodine.
The hydrogel delivery device may be used to deliver iodine-generating
formulations without the necessity of removing the device from the body
region, such as
the vagina, following its use. Instead, it solvates to a gel-sol, mucoid-like
product, which
coats the cervix and vaginal walls, and lays down an impenetrable spermicidal
and
microbicidal barrier of elemental iodine lasting from 8 to 24 hours following
its insertion
intravaginally, and dissipates slowly from the vagina over a period of days as
normal
mucoid-like fluid escaping the introitus. An example of an indication best
suited for the
use of a hydrogel inventive device is for the treatment of BV. In this
instance, the device
is cast in liquid hydrogel form into a flattened disc shaped mold with a
diameter of from
4.5 to S.5 cm, and a thickness of 0.3 to 0.7 cm. Variations in the diameter of
the disc, or
the general shape of the device (e.g., concave discs, tampons, etc.) may be
made in
certain instances to accommodate differences in the anatomy of some vaginas.
This
design was chosen to allow the disc to be inserted into the vagina against the
base of the
cervix. The disk-shaped hydrogel device, once inserted, will egress
microbicidal activity
concomitant with solvation and coat the cervix and vaginal walls with a thin
layer of the
elemental iodine generating formulation encapsulated within the solvated
hydrogel.
Examples of suitable hydrogel. polymers include, for example, from 0.5 to 2 %
high or
medium viscosity alginic acid, B.F. Goodrich Carbopol 971 PNF (or crosslinked
analogues of this polyacrylic acid such as B.F. Goodrich Carbopol 971 PNF or
NoveonT"'
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
42
AA1), or 1:1 mixtures of alginic acid and Carbopol, adjusted from a pH of
about 3.7 to
4.2 with NaOH. The low pH of the hydrogel is important in providing H+ which
are
consumed in forming nascent elemental iodine (see example 8), and in
maintaining the
pH of the vaginal fluid at its normal pH (e.g., ranging from about 3.7 to
4.5). The low
pH has an additional advantage in that it also confers some microbicidal
activity to the
hydrogel formulation.
Critical fabrication steps of the hydrogel device to encapsulate the elemental
iodine generating formulations include: (1) prechilling the gel-forming
solution to less
than 4 °C but not below freezing temperatures; (2) adding and mixing in
an elemental
iodine generating formulation into the gel solution, (3) casting the mixture
into a mold;
and (4) rapidly freezing and lyophilizing the mixture. The final product
contains the
elemental iodine generating compounds encapsulated within the desiccated
fibers of the
hydrogel in a dormant state. Upon insertion and contact with body fluids {for
example,
vaginal fluids), the device spontaneously generates elemental iodine as a
result of the
release of the elemental iodine generating compounds into solution concomitant
with
solvation of the hydrogel polymer.
An alternative method of manufacturing the hydrogel device without use of a
mold is to cast the hydrogel premixed with elemental iodine generating
formulations in
sheets of from about 0.3 to about 0.5 cm thick, lyophilize the sheets, and
then trim the
sheets to the desired shape. Trimming is done with any suitable shearing
device, knife or
blade.
The following example illustrates fabrication of a specific embodiment of the
inventive device in the form of a hydrogel membrane containing anti-infective
properties
upon solvation in body fluids. A 2% {by weight) "medium viscosity" sodium
alginate in
distilled water was made up and mixed with an equal volume of 2% Carbopol 971
(B.F.
Goodrich) made up in distilled water to yield a composite 1 % viscous gel
solution, pH
3.95, made up of equivalent weights of alginate and Carbopol. The viscous gel
solution
was chilled to about 4 °C and 100 mM potassium iodide in water was
added and mixed
thoroughly to yield a final concentration of from about 1 mM to about 5 mM
potassium
iodide. A similar gel mixture using 100 mM sodium iodate made up in water was
prepared to yield an equal volume of from about 1 to about 5 mM sodium iodate.
The
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
43
two gel mixtures were prechilled to less than 2 °C and then rapidly
mixed together. The
combined gel mixtures were cast in a flat bed plastic tray prechilled below 0
°C. The
cast mixture was then plunged into a -70 °F freezer so that the colloid
mixture quickly
froze into a solid sheet. The total process procedure, from the time of mixing
the iodide
and iodate gel mixtures together until they are frozen solid as a sheet,
should not exceed
from 3 to 5 minutes. Once frozen, the sheet was transferred to a lyophilizes
to sublime
off the water under high vacuum using a vacuum pump. The final product was a
fine,
highly porous, lightweight, sponge-like sheet (approximately 0.3 to 0.5 cm in
thickness),
red-brown to slightly purple in color. Once lyophilized, the sheets can be
cut, or pressed
under a hydraulic press, into varying shapes as desired such as a circular
disc of from
about 4.5 to about 5.5 cm in diameter for vaginal delivery, for example, such
as for an
indication to treat BV.
Other shapes, such as cylinders, square films, etc. may be cut from the
desiccated
sheets as desired. An inventive hydrogel device, as described herein, will
form nascent
elemental iodine within the range of from 5 to 100 ppm, and within seconds of
coming
into contact with body fluids. Elemental iodine formed in the hydrogel device
dissipates
over a period of from approximately 4 to 12 hours after activation of the
device (e.g.,
after initiation of free elemental iodine formation has occurred).
A variation of the this process for forming inventive hydrogel devices in the
form
of a membrane involves mixing either glucose oxidase {D-glucose:oxygen 1-
oxidoreductase; EC 1.1.3.4) {from about 10 to about 500 pg/ml) or horseradish
peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) (from about 2
to
about 20 ug/ml) or both in from about 0.5 to about 2 % alginate-Carbopol gel
solution
made up in water at room temperature. Potassium iodide is then added to this
mixture to
a final concentration of from about 1 to about 10 mM. This hydrogel mixture is
then
frozen and lyophilized in sheets as described above for the iodide/iodate
hydrogel
mixture. The final sponge-like product has an off white color, and can be
stored at room
temperature without loss of nascent elemental iodine generating activity. Upon
insertion
into body fluids containing glucose, the inventive hydrogel device solvates
within 5 to 20
minutes concomitantly producing elemental iodine within the solvated gel
mixture in the
range of 5 to 100 ppm.
CA 02335055 2000-12-13
WO 99/b5538 PCT/US99/13898
44
A variety of anti-infective medical devices may be provided in accordance with
the invention, including catheters, guidewires, gloves, protheseses, implants,
and
contraceptive devices. A part of the medical device may be formed of the
polymeric
matrix containing an oxidant producing component throughout the part, or it
may have a
layer of the polymeric material containing an oxidant producing component.
Figure 10
illustrates a transverse cross-sectional view of a catheter 10 having a
catheter shaft 11
formed of a polymeric matrix 12 containing an oxidant producing component 13
throughout the shaft. Figure 11 illustrates a transverse cross-sectional view
of a catheter
14 having a catheter shaft 15 having a body 16 and a layer of a polymeric
matrix 17
containing an oxidant producing component 18 in the polymeric matrix. In the
embodiment illustrated in Figure 1 l, the layer 17 is on an outer surface of
the catheter.
However, it should be obvious that the layer may be on an inner surface of the
body 18
or between inner and outer layers of the device. Although not shown, the
polymeric
matrix may contain one or more of an oxidizing agent, a reducing agent, and a
proton
source, depending on the nature of the oxidant producing component.
One embodiment of the invention comprises a self sterilizing glove. The self
sterilizing gloves may be formed by casting the polymer base over a suitable
mold to
form left- and right-handed gloves wherein at least one layer, preferably the
last layer,
containing the anti-infective component, contains all but a body fluid, the
latter provided
with solvation of the reactants by sweat, or other body fluids entering a
ruptured glove
exposed to body fluids, and wetting the inner surface of the glove coated with
anti-
infective reactants. Removal of the molded glove from its casting form with
inversion of
the glove presents the anti-infective coated polymer in close proximity to the
skin where
activation provides an anti-infective barrier to the wearer of the glove. The
preferred
embodiment involves leaving the exterior side of the glove free of anti-
infective
encapsulated reactants with only a thin skin of encapsulated anti-infective
reactants
coated on the side of the glove presented against the skin of the hand. A
variety of
suitable polymeric materials may be used including polyvinyl chloride, latex,
polyurethane, or other suitable hydrophobic polymer commonly used in the
manufacture
of gloves. In the embodiment in which the polymeric material is typically
processes in
aqueous solutions, the polymeric matrix preferably does not contain one or
more
CA 02335055 2000-12-13
WO 99/b5538 PCTNS99/13898
reactants required for reacting with the oxidant producing component to form
the
oxidant. For example, one or more of an oxidizing agent, reducing agent, or
proton
source may be provided as a separate layer. In one embodiment, a proton source
is
provided as a layer dusted onto a surface of the glove. Figure 12 illustrates
a longitudinal
cross-sectional view of a glove 20 formed of a polymeric matrix 21 containing
an
oxidant producing component 22 and having a proton source 23 dusted onto an
inner
surface of the glove.
An example of the embodiment is as follows: using latex rubber, paint over a
suitable mold, or dip the mold into the latex polymer, and air dry the latex
to allow for
the build up from three two six layers of latex coating as a polymer skin
coating the
mold. Thereafter, paint over the outer latex skin a mixture of 2% by weight
sodium
iodide, 8 % sodium iodate, ground up as a fine powder of less than or equal to
about 200
microns and suspended in latex polymer, and an additional two to three layers
of iodide-
iodate loaded latex allowing for the encapsulation of precursors for the
formation of
elemental iodine within the final layers of latex coating the mold. Upon
drying, lightly
dust the inverted glove with B. F. Goodrich Carbopol 971, 974, Polycarbopol,
finely
ground salts of sodium or potassium dihydrogen phosphate, finely ground
pectin, or any
other suitable proton source confernng to the glove's surface, when wetted, a
pH of
approximately 3.0 to 6.0, which allows for the formation of anti-infective
elemental
iodine upon wetting of the glove concomitant with solvation of encapsulated
iodide and
iodate. The iodide and iodate may each be varied in the polymer base from a
weight
percent relative to the polymer of from 0.05% to 10 % by weight as desired to
achieve
varying free levels of iodine formation concomitant with wetting of the glove
(providing
a source of proton is also made available). In the absence of a proton source,
no
elemental iodine is detectable even with wetting of the surface encapsulated
with iodide
and iodate. Formation of elemental iodine is evident by the presence of a
yellow hue to
the inner surface of the glove with wetting of its inner surface. The
preferred
concentration of elemental iodine necessary to confer to the glove anti-
infective
properties ranges from about 2 to 100 ppm.
As mentioned above, the medical device of the invention may produce a variety
of suitable anti-infective oxidants other than elemental iodine, including
hydrogen
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
46
peroxide. nitric oxide, hydroxyl radical, hypohalites, haloamines,
thiocyanogen, and
hypothiocyanite. The concentration of all solid powdered anti-infective
precursors
encapsulated within the polymer base should be in the range from about 0.01 %
to about
16% by weight relative to the polymer mass. Enzyme activity dispersed within,
or
attached to the surface, of the polymer. should range from no less than about
50 units to
an upper range of about 330,000 units per gram solid. The preferred
concentration range
of halides egressing from the polymer base upon solvation should preferably
range from
about 1 mM to no more than about 200 mM. The concentration of thiocyanate
egressing
from the polymer, if encapsulated within the polymer base, should not be less
than about
1 micromolar nor exceed about 5 millimolar.
The precursors of the oxidants are contained as solids into a hydrophobic
polymer
base as discussed above. The hydrogen peroxide generators include nonenzymatic
reactants and enzymatic reactants. The nonenzymatic reactants include
percarbamide,
perborates such as alkali metal perborates such as sodium perborate
monohydrate,
sodium perborate tetrahydrate, sodium percarbonate; calcium peroxide, ammonium
persulfate, benzoyl peroxide, cumyl hydropeoxide, 3-morpholinosydnonimine
hydrochloride (SIN-1), and similar peroxy acid precursors and hydrogen
peroxide
addition compounds in which hydrogen peroxide is a product formed by
spontaneous
hydrolysis or solvation of the primary precursor compound. The enzymatic
reactants
include substrate oxidoreductases illustrated as in the following coupled
reactions:
glucose + glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4)
encapsulated as dry solids within polymer base or with enzyme noncovalently or
covalently attached to polymer surface using enzyme immobilization techniques
known
to those familiar with the art (see below); xanthine (or hypoxanthine) +
xanthine oxidase
(EC 1.1.3.22) similarly incorporated as in the case of the glucose/glucose
oxidase (D-
glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) reactants; spermine, putrescine,
benzylamine {and related amine substrates) of diamine oxidase; and comparable
oxidoreductases in which the substrate serves as an electron donor catalyzing
reduction
of molecular oxygen to yield hydrogen peroxide either as a direct product or
via
dismutation of superoxide formed as a precursor of hydrogen peroxide
formation. The
term benzylamine of diamine oxidase should be understood to mean amine:oxygen
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
47
oxidoreductase[deaminating] [pyridoxal-containing]; EC 1.4.3.6.
The superoxide, nitric oxide and hydroxyl radical generators include, SIN-1*,
S-
nitroso-N-acetylpenicillamine (SNAP), and NONOate [N-(2-arninoethyl)-N-(2-
hydroxy-
nitrohydrazino)-1,2-ethylenediamine] encapsulated as solids within the polymer
base and
activated upon wetting of the polymer as generators of NO; xanthine + xanthine
oxidase
encapsulated as dry solids within the polymer base or with xanthine oxidase
noncovalently or covalently attached to the polymer surface, and SIN-1 *
encapsulated as
a solid powder within the polymer base, as generators of superoxide, hydrogen
peroxide
and hydroxyl radicals. SIN-1 by itself is capable of generating superoxide,
hydrogen
peroxide, hydroxyl radical, and nitric oxide concomitant with its solvation
and
subsequent hydrolysis.
Hypohalites can be generated by a polymeric material containing one of the
above H20z generators in combination with myeloperoxidase {donor:hydrogen-
peroxide
oxidoreductase; EC 1.11.1.7) also contained within the polymer base as a dry
powder
mixture, or with myeloperoxidase noncovalently or covalently attached to the
polymer
surface. In this formulation, hypochlorous acid is formed upon wetting of the
polymer is
a body fluid due to the ubiquitous presence of chloride ions in solution
wherein chloride
ion and H202 serve as substrates of myeloperoxidase in forming hypochlorite.
Alternatively, hypoiodite, or hypobromite, both of which also exhibit strong
anti-
infective activities, may be formed with inclusion of the alkali salts of
iodine and
bromine, respectively, encapsulated as dry powders within the polymer base.
Haloamines can be generated by encapsulation of hypohalite generators in the
base polymer in combination with primary or secondary amines such as taurine,
histidine, spermine, lysine, glycine and similar aliphatic and cyclic primary
and
secondary amines which upon exposure to hypohalites form the corresponding
long-lived
haloamines such as taurine chloramine , histidine chloramine, spermine
chloramine, and
the like.
Thiocyanogens and hypothiocyanites can be generated by encapsulation of the
above H2O2 generators within the polymer base in combination with
myeloperoxidase
(donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7), lactoperoxidase
(donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7), horseradish peroxidase
CA 02335055 2000-12-13
WO 99/65538 PCT/US99113898
48
(donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7), or other donor:hydrogen
peroxide oxidoreductase, encapsulated within or attached covalently or
noncovalently to
the polymer surface, and a dry powder alkali salt of thiocyanate, wherein H2O2
and
thiocyanate serve as substrates of the peroxidase in the formation of
thiocyanogen, or its
hydrolysis product, hypothiocyanite, in fluid coming into contact with the
polymer upon
solvation and egress of the encapsulated reactants.
Immobilization of Enzymes by Covalent or Noncovalent Methods to the Polymer
Surface
In the embodiments having enzymatic reactants, the enzymes can be attached to
the polymeric material using conventional methods. For example, methods for
the
covalent and noncovalent attachment of enzymes to silicone and other
hydrophilic and
hydrophobic polymers include diazotization, amide bond formation, alkylation
and
arylation, amidation as well as ionic charge associations and hydrophobic
binding as
described in detail in:
Miller, R.E. (1972) Attachment of Enzymes to Siliceous Materials, U.S. Pat.
3,669,841.
Zaborsky, O.R. (1974) in, Immobilized Enzymes, CRC Publishing, Cleveland, OL.
Avrameas, S. et al. (1990) Immobilization of Active Protein by Cross-Linking
to Inactive
Protein. U.S. Pat. 4,970,156.
Okamura, S. et al. (1976) Method for Manufacturing Medical Articles Composed
of
Silicone Rubber Coated with Collagen. U.S. Pat. 3,955,012.
Rohrback, R.P. et al. (1980) Support Matrices for Immobilized Enzymes. U.S.
Patent
4,206,259.
Learn, M.T. (1987) 1,1'-Carbonyldiimidazole-Mediated Immobilization of Enzymes
and
Affinity Ligands. Meth.-Enzymol. 135, 102-117.
Miron, T. and Wilchek, M. (1987) Immobilization of Proteins and Ligands Using
Chlorocarbonates. Meth. Enzymol. 135, 84-90,
incorporated by reference in their entireties.
Wetting of the polymer containing the encapsulated reactants during attachment
of the enzyme to the surface of.the polymer is not critical, nor does it
defeat the
performance of the polymer in releasing anti-infective activity. The period
required for
covalent andlor noncovalent attachment of the enzyme catalyst is of a brief
duration,
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
49
generally over a period of a few hours, wherein the solvation of encapsulated
reactants is
minimal relative to the reservoir of reactants retained within the polymer.
Furthermore,
by judicious choice of the attachment method the pH, oxygen tension, or other
critical
substrate, can be manipulated to preclude formation of reactive products
during enzyme
attachment. In the case of donor:oxygen oxidoreductases (for example, glucose
oxidase
(D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4)), attachment of the enzyme
under
anaerobic conditions using aqueous solutions purged of oxygen deprives the
enzyme of
oxygen as a co-substrate in the formation of hydrogen peroxide, and therefore
prevents
premature formation of anti-infective products. Similarly, the exclusion of a
halide
source while coupling myeloperoxidase precludes formation of a hypohalite
during the
immobilization of myeloperoxidase to the surface of the polymer base. Upon
completion
of the enzyme immobilization step, the polymer can be dried by air, or by
blotting on a
suitable absorbent such as paper or felt, so that the residual moisture left
on the surface
precludes any further solvation of encapsulated reactants.
In certain instances where the chemistry precludes attachment of the enzyme to
the surface of the polymer directly because of too rapid of release of
reactants from the
polymer during the attachment phase, and where entrapment of enzyme within the
polymer base is deemed too costly or inefficient, the enzyme can instead be
immobilized
to a second, thin polymer film lacking reactants. The latter film containing
immobilized
enzyme can be attached to the implant polymer containing encapsulated
reactants in the
form of an elastic band, grid, or patch, bringing the enzyme in close
proximity to the
surface of the polymer containing encapsulated reactants. In this manner the
enzyme
serves to catalyze reactants into anti-infective products as the reactants
solvate and egress
to the surface of the implanted polymer.
Example 1
This example illustrates the incorporation of iodide into a silicone disc
device and
long term release rates of iodide upon submersion and washing of the device in
buffer.
Finely ground sodium iodide {3 g), prepared in a mortar and pestle, was mixed
into 10 g
of RTV silicone elastomer (polydimethylsiloxane) to which was also added 1 g
dibutyl
tin dilaurate catalyst stock solution. The ground crystalline sodium iodide
powder
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
recovered from the mortar and pestle was added last to the polymer base after
thorough
mixing of the catalyst into the silicone, and the silicone then poured into
5.0 cm diameter
Petri dishes to a depth of ~ 0.3 cm in thickness. After 24 hrs, the cured disc
was
removed, thoroughly rinsed in 10 mM sodium phosphate buffer, pH 5.6, made up
in 150
mM NaCI, and then placed into a 150 ml beaker containing 10 ml of the same
buffer. At
varying intervals (see Figure 1 ), including an initial t = 0 measurement,
buffer was
drained from the beaker and device, and set aside for analysis of iodide
content. The
release of iodide was measured after mixing H202 (~ 56 mM) with 1 ml aliquots
of the
sample washings. The assay tracked formation of elemental iodine at 350 nm in
a
Shimadzu UV-265 double beam spectrometer against a standard calibration curve
constructed with known quantities of sodium iodide made up in the same buffer
and
worked up in the same manner. Fresh 10 ml aliquots of buffer were washed over
the
device for analysis of subsequent release of iodide over the next interval,
and this process
was repeated over a period of approximately 30 days. In between, the device
immersed
in buffer was left on a shaking rocker platform at room temperature.
Precautions were
taken to minimize evaporation between sampling intervals by covering the top
of the
beaker with plastic wrap.
Figure I shows that sodium iodide, incorporated at a ratio of solid to
elastomer of
30% into the polymer base of the fabricated device, allowed for the release of
iodide
(upon immersion and sequential changes in buffer). The peak iodide release was
at
around SO to 60 mM (in a fluid volume of 10 ml buffer per washing interval).
The
capacity of the device to restore iodide to this level with sequential changes
in buffer
remained relatively constant over the first 350 hrs, and then declined to ~ 20
mM by
around 600 hrs of continuous immersion and rinsing of the device in buffer.
Calculations
of iodide recovery, relative to the iodide initially available in the device,
indicated that by
600 hrs of continuous immersion and washing under the above conditions ~ 90%
of the
iodide was leached from the device.
Example 2
This example illustrates the release of glucose oxidase and horseradish
peroxidase
encapsulated within a device fabricated from a silicon elastomer.
Specifically, the device
CA 02335055 2000-12-13
WO 99/65538 PCTlUS99/13898
51
was fabricated with a glucose oxidase/horseradish peroxidase and iodide
formulation into
a disc with silicone elastomer. The subsequent release of the formulation from
the
device was measured after immersion and continuous bathing in buffer. RTV
Silicone
elastomer (10 g, polydimethyl siloxane with silanol end caps) was mixed with
silicic
ester dibutyl tin dilaurate catalyst ( 1. I g), and into this uniform mixture
50 mg crystalline
glucose oxidase (D-glucose:oxygen I-oxidoreductase; EC 1.1.3.4), 5 mg
crystalline
horseradish peroxidase (donor:hydrogen-peroxide oxidoreductase; EC I .11.1.7)
and 3 g
of finely ground sodium iodide were slurned. The slurry was poured into 5.0 cm
diameter Petri dish to a thickness of ~ 0.1 cm, cured for approximately 24
hours at room
temperature, removed from the mold, briefly rinsed in distilled water, placed
in a 150 ml
beaker, wetted with 1 ml of sodium phosphate (10 mM), pH 5.6, also containing
ISO mM
NaCI, then left on a continuous rocker platform. This allowed for the buffer
fluid to
continuously wash across the device's surface. At timed intervals, buffer was
drained
from the beaker and replaced with an equivalent volume of fresh buffer.
Between
intervals the beaker was kept tightly covered to prevent evaporation.
To evaluate egress of glucose oxidase and horseradish peroxidase generating
activities from the fabricated device, wash buffer (200 p.l), in which the
device was
immersed, was mixed with an equal volume of 10 mM sodium phosphate, pH 5.6,
made
up in 100 mM potassium iodide and 100 mg/dl glucose. With glucose and iodide
additions to the test washings there was observed a rapid development of
yellow
coloration in the assay mixture. The yellow coloration was confirmed by
spectral scans
on a Shimadzu UV-265 double beam spectrometer to be characteristic of I3-
formation
(e.g., complexation of elemental iodine with iodide), indicating the release
of glucose
oxidase and horseradish peroxidase from the device. This conclusion, that
glucose
oxidase and horseradish peroxidase were egressing from the device and at
levels
sufficient to catalyze formation of nascent elemental iodine, was further
confirmed
through a spot test for glucose oxidase. Hence, omission of glucose resulted
in no color
formation.
The formation of elemental iodine was also confirmed by extracting an aliquot
of
the yellow colored assay solution with chloroform and observing elemental
iodine in the
chloroform layer. The lower chloroform layer took on a characteristic pink-
violet color
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
52
typical of elemental iodine (absorbance max, 508 nm). Horseradish peroxidase
was also
confirmed to be egressing from the disc by conducting a separate spot test for
peroxidase
activity using o-dianisidine as substrate in place of iodide. This latter
substrate did not
show the propensity to oxidize readily in the presence of Hz02. However,
peroxidation
of o-dianisidine was evident upon replacing iodide with o-dianisidine
substrate in the
standard assay. Furthermore, control tests run with glucose oxidase alone
showed that
the formation of triiodide (e.g., yellow coloration) was delayed well beyond
30 seconds
under the experimental conditions employed, all of which therefore confirmed
the egress
of both glucose oxidase and horseradish peroxidase from fabricated device
immersed in
wash buffer.
A 30 second test for visual detection of elemental iodine formation in the
form of
I~- was used to semi-quantitatively track the device's reservoir capacity in
releasing
glucose oxidase and horseradish peroxidase to the wash buffer with repeated
submersion
and washing. Table 1 summarizes the results of these experiments.
Table l.Diffusion of GO and HPO from Silicone Device into Immersion Buffer v.
Washing Interval
Sampling Interval GO/HPO Released intoComments
Post Buffer Washing?
Immersion of Disc
(hrs)
0 = test on wash buffer
at t = 0.
4.5 + very strong (<30 sec)
29.0 + " "
50.8 + " " "
75.8
+
97.8 +/- weak response; color
in 30 -
60 sec
125 +/_ .~ .<
153 +/- ~. ~.
174 +/-- Very weak; color >60
sec
196 +/--- Very weak; color > 120
sec ~
At the sampling intervals indicated, buffer ( 10 mM sodium phosphate, pH 5.6,
made up in 150 mM NaCI) was removed for testing and replaced by a fresh 1 ml
aliquot.
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
53
Controls (exclusion of glucose from test mixture) tested negative for yellow
coloration
(triiodide). These data show that a significant release of glucose oxidase and
horseradish
peroxidase from the device occurred under the conditions in which it was
fabricated and
tested over a period of approximately 4-5 days. These data further show that
residual
iodine activity continued to egress from the device, albeit at lesser levels,
over a period
up to 8 to 9 days duration.
Example 3
This example illustrates iodate reduction and conversion to elemental iodine
and
microbicidal tests on fabricated devices encapsulated with iodate and iodide
in silicone-
based polymer. Based upon evidence that many body fluids are rich in reducing
compounds, antioxidants, and the like, alternate methods of generating
elemental iodine
de novo from iodide and iodate were investigated using Brain Heart Infusion
(BHI)
media to mimic complex body fluid conditions. BHI is a rich source of reducing
compounds of the type found in body fluids. The formation of elemental iodine
de novo
from iodide and iodate in BHI media was confirmed by titrating solutions of
BHI with
incremental additions of iodide and iodine pentoxide (the anhydride of
iodate), either in
combination, or with iodine pentoxide alone. Following additions of trace
amounts of
iodide in combination with iodine pentoxide (total iodine < I mg/ml broth
media), the
BHI media took on an intense yellow-orange hue, indicative of I3- formation
(e.g.,
formation of elemental iodine and its complexation with iodide ion). The
presence of
elemental iodine was confirmed by extraction of BHI media titrated in this
manner with
chloroform, which revealed the characteristic intense violet color of
elemental iodine
associated with its partitioning into the lower chloroform layer (absorbance
max, 508
ntn). These data were interpreted as evidence of robust elemental iodine
production
arising by the reductive conversion of iodate to elemental iodine, but also as
evidence
that iodate was oxidizing added iodide into elemental iodine in accordance
with
theoretical expectations based upon the chemistry of iodate.
This latter conclusion was based upon the observation that addition of iodate
(in
the form of iodine pentoxide) alone to BHI media did not alter the coloration
to the
media. Further additions in excess of ~ 1 mg/ml, however, ultimately led to a
similar set
CA 02335055 2000-12-13
WO 99/ø5538 PCT/US99/13898
sa
of findings to those seen with additions of iodide and iodate to the broth
media. These
results were interpreted as evidence of conversion of iodine pentoxide to
iodate,
reduction of iodate to iodide by reducing equivalents present in BHI, and
subsequent
oxidation of iodide to elemental iodine by further additions of iodine
pentoxide to the
media. The interconversions appeared complex and dependent upon the rate of
reduction
of elemental iodine and iodate to iodide by reducing equivalents in the media,
as opposed
to the opposing rates of oxidation of iodide to elemental iodine caused by the
presence of
iodate in the broth media and the rate at which iodine pentoxide spontaneously
hydrolyzes to iodate.
Disc shaped silicone devices were prepared as in example 1, except
formulations
of iodide and iodine pentoxide, or iodine pentoxide alone and in combination
with NaCI
as a carrier were incorporated into the silicone. The formulations were aimed
at testing
the device's capacity to produce microbicidal activity upon submersion in BHI
broth
media. Specifically, sodium iodide (3 g) was ground to a fine powder under
anhydrous
conditions with iodine pentoxide ( 1 g) and dispersed in 10 g of silicone
elastomer
premixed with silicic ester dibutyl tin dilaurate catalyst, then poured into
s0 mm Petri
dishes and processed as in Example 1. Smaller discs were cut from the device
using a
hole punching tool in producing silicone tablets of ~ 6 mm diameter. These
were placed
in BHI media, previously adjusted to pH 4.0, at 1 tablet per ml, and the BHI
media
containing the tablets then inoculated with test organisms, as noted in Table
2 (below).
A similar device was prepared using NaCI in place of sodium iodide at 2g per
10
g of silicone polymer base. Tablets from this device were also tested for
microbicidal
activity upon introduction to inoculated BHI media as described in Table 3
(below). As
expected, all of the tablets formulated with both iodide and iodine pentoxide
produced an
intense yellow coloration immediately upon contact with BHI media, indicative
of
instantaneous elemental iodine formation. Tablets with only iodine pentoxide
present
had no discernible effect on the coloration of the BHI media.
Table 2. Microbicidal Activity of iodide/iodate Encapsulated Silicone Tablets -
Recovered CFU/ml Following Inoculation in BHI Media and Saline.
CA 02335055 2000-12-13
WO 99/!5538 PCTNS99/13898
SS
Inoculation Medium
Organism Inoculation
Time (hrs)Saline BHI, pH
4.0
C. albicans0 66000 40000
24 <10 <1000
48 nd <10
L. casei 0 500000 500000
24 <10 <1000
148 Ind ~<10
Incubations conducted at 3S° C. nd = not determined.
Table 3. Microbicidal Activity of iodine pentoxide Encapsulated Silicone
Tablets -
Recovered CFU/ml Following Inoculation of Test Media.
Inoculation Medium
Organism Inoculation
Time (hrs)Saline BHI, pH
4.0
C. albicans0 140000 100000
3.5 <10 <1000
22 <10 <10"
Incubations conducted at 3S° C. nd = not determined.
a chloroform extraction on residual culture media - no appearance of violet
coloration.
b chloroform extraction on residual culture media -strong violet coloration
indicative of
elemental iodine presence.
Figure 2 also shows the kinetic release of iodine pentoxide from discs
prepared in
the same manner as in the microbicidal studies summarized in Table 3. The
discs were
suspended in 100 mM sodium citrate, pH 4.0, at 1 tablet per ml, but using
different mass
concentrations relative to the polymer base used in fabricating the silicone
device. The
concentration of iodate released was proportional to the mass encapsulated
into the
polymer (Figure 2). In these experiments the total salt (NaCI) mixed into the
silicone
polymer was held constant at 30% and comprising iodine pentoxide and NaCI as
necessary to maintain a constant salt:polymer ratio, but at concentrations of
iodine
pentoxide per unit polymer mass of 2% and 10%, respectively. Complex media,
such as
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
56
BHI, had no discernable impact on the solvation and diffusion rates of iodine
pentoxide
as similar rates of iodine pentoxide release were seen substituting BHI media
in place of
citrate buffer.
The data from Tables 2 and 3 show that elemental iodine mediated killing of
the
microorganisms tested. These data were generated as a result of fabricating
the device
with varying concentrations of iodide in combination with iodine pentoxide and
placing
tablet samples from the device within the BHI media rich in reducing
compounds, or
saline. The organisms supplied their own source of reducing compounds to the
device
tablets. The levels of iodate required for effective microbicidal activity
appeared to be
« 5 mM, based upon measurements of iodate released from the tablets, and by an
examination of the killing interval after introduction of the tablets to
inoculated cultures
(see, for example, Tables 2 and 3, and Figure 2). For example, the data in
Table 3
indicates effective killing occurred within 3 to 4 hours of exposure to the
iodine
pentoxide tablets. Assuming all of the iodate released into the media could be
converted
to elemental iodine, this suggests an upper limit of iodine in the BHI media
could not
theoretically exceed ~ 125 mg/dl (e.g., S mM elemental iodine). The elemental
iodine
concentration was found experimentally to be far less than this calculation
(see below).
Chloroform extracts made on the cultured BHI media in which iodate was found
to be
present also showed no evidence of significant elemental iodine accumulating
(i. e., no
coloration of the chloroform layer occurred) affirming that little actual
elemental iodine
accumulated in the broth medium. Without being bound by theory, these latter
observations indicate that elemental iodine killing likely and predominantly
occurred at
the microbe's cell wall (Tables 2 and 3), and possibly through release of
reducing
compounds on the microbe's cell surface. This would cause de novo formation
and
uptake of elemental iodine into the lipid bilayer of the microbial cell
membrane.
These data indicate that elemental iodine concentrations required to affect
microbial killing are generally « 0.01 % (that is, as much as two orders of
magnitude
below the iodine content of povidone-iodine solutions). The lower elemental
iodine
concentrations required and produced by the inventive device, relative to
iodophor
vehicles such as povidone-iodine, are attributed to the fact that iodate was
released
slowly over a period of time using the fabricated silicone device as the
vehicle for its
CA 02335055 2000-12-13
WO 99/b5538 PCTNS99/13898
57
presentation in solution. Further, recycling of iodate to iodide, and then
back to
elemental iodine, likely occurred continuously as fresh iodate continued to
egress from
the device and encounter reducing compounds, and iodide recycled from
elemental
iodine formed in an earlier cycle, in its path. Thus, even trace quantities of
iodide can be
envisioned to recycle in the reaction media until taken up by the microbial
cell in the
form of elemental iodine, whereupon killing of the microbe then ensues.
Example 4
This example illustrates the microbicidal activity and optimization of iodate
and
iodide formulations for de novo formation of elemental iodine. Experiments
were
performed to optimize formulations used in fabricating the inventive device
formulated
with silicone elastomer. Finely ground iodate and iodide were mixed into
silicone
elastomer in various loadings relative to the elastomer. The polymer was
allowed to cure
with dibutyl tin dilaurate catalyst additions, and then devices were prepared
(0.6 cm
diameter 0.3 mm thick) using "hole punch" tablets from the disc shaped device
to test for
microbicidal activity using C. albicans inoculated BHI. BHI media was adjusted
to pH
4.0 with HCI, and an inoculum of approximately 1 x 105 CFU/ml C. albicans
(ATCC
66027) was added to the broth media. Tablets obtained from the fabricated
device were
suspended in the inoculum at 1 tablet/ml. At varying intervals, aliquots of
the inoculum,
incubated at 35 °C in air, were subcultured to sheep blood agar plates
and incubated for
an additional 24 hours at 35 °C in air to determine the effect of the
varying formulations
on the C. albicans inoculums.
Tablets obtained from devices formulated in the range of 1 % to 16% by weight
iodide alone relative to silicone elastomer (total salt, 30% by weight with
the difference
made up with NaCI as a carrier salt) showed no microbicidal activity. Tablets
made up
in the same manner, but with iodate alone ranging from 0.5 to 12% by weight,
showed no
microbicidal activity against C. albicans at 24 hours exposure. However, in
the range of
4 to 12% iodate a 1 to 2 log decrease in growth at 48 hours exposure, and <10
CFU/ml
were found with 72 hours exposure.
Tablets obtained from silicone devices made up with varying weights of iodate
ranging from 2 to 4% by weight, and iodide ranging from 0.1 to 0.25% by weight
CA 02335055 2000-12-13
WO 99/65538 _ PCTIUS99/13898
58
combinations (additional weights of NaCI added to bring the final salt weight
relative to
silicone to 30%), showed no microbicidal activity. However, with increasing
weights of
iodide in excess of 0.5% by weight in the presence of 4% by weight or greater
iodate,
complete killing of C. albicans occurred within 24 hours of submersion of the
tablets
within the BHI inoculums: Therefore, the lower limit of the formulation needed
to effect
killing within 24 hours exposure in complex Bl-II media amounted to
approximately 4%
iodate, 0.5% iodide and 24.5% NaCI salt (ground to < 200 microns) all by
weight
suspended in the silicone base used in fabricating the devices. Further tests
revealed that
formulations varying from 4% to 8% iodate, and from 2% to 16% iodide all by
weight
were very efficient in killing C. albicans with complete killing occurring in
less than 4
hours of submersion of the silicone tablets within the BHI inoculums.
PVP was also found to improve the stability of the silicone formulation by
acting
as both a desiccant and an iodophor, such as by preventing moisture from the
atmosphere
from prematurely activating the iodide salts mixed into the silicone
elastomer. By
inclusion of from about 1% to about 10% finely ground PVP by weight together
with
iodate and iodide in fabricating the microbicidal disc shaped device, the
final device
obtained after curing of the elastomer showed less tendency to express
elemental iodine
upon exposure to air over time. No adverse effects of including PVP in the
salt
fonmulations were observed with regard to alteration of the device's
microbicidal
activity. The optimal iodide salt formulation based upon the tablet tests used
was 8%
iodate, 2% iodide and ZO% PVP with omission of NaCI from the final salt
mixtures. The
latter "carrier" salt was found to provide no obvious benefits in fabricating
the device,
nor did it appear to have any significant effect on the release rates of the
salt formulations
encapsulated within the silicone device.
Concomitant with the microbicidal killing studies, measurements were made on
the release of iodate, iodide and formation of elemental iodine during
submersion of the
tablets in citrate buffered solutions. The release rates were experimentally
indistinguishable whether tablets representing the device embodiment were
submerged in
BHI or 100 mM Citrate buffer, pH 4.0, whereas reducing compounds present in
BHI
consumed some of the elemental iodine as it was formed when the tablets were
immersed
in the latter media. For this reason, the chemical profile for release of the
iodide and
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
59
iodate, and elemental iodine formed, was tracked in citrate buffer. Figure 3
shows the
release of iodate, and iodide , from submerged tablets ( 1 tablet/ml in
citrate buffer)
incubated at room temperature over a period of approximately 32 hours. In
these
experiments, iodate was tracked by drawing 20 ~1 aliquots of the test
solutions which
were subsequently allowed to oxidize iodide to elemental iodine in the
presence of
excess iodide, and by which the formation of I3- was then quantitated
spectrally at 350
nm in a standardized assay. A calibration curve using the same assay was
constructed
with known concentrations of iodate from which the concentration of iodate
released
from the tablets was determined as a function of submersion interval (see
Figure 4).
Iodide was tracked by obtaining 200 ~.1 aliquots and oxidizing the iodide to
elemental
iodine in the presence of excess iodate, and extracting the latter into
chloroform for
spectral quantitation at 508 nm against a calibration curve constructed under
identical
assay conditions, but with known concentrations of iodide. The results of
these chemical
tracking experiments, matched with the microbicidal killing studies, and
revealed that a
critical media concentration of iodate in the range of 1 to 2 mM, and iodide
concentration
of from 0.5 mM or higher, was necessary to effect C. albicans killing. Tablet
formulations, which failed to kill C. albicans within the first 24 hours, or
less, failed to
do so because the threshold levels of iodate and iodide were not achieved.
Figure 4 shows the accumulation of elemental iodine in the citrate buffer
tracked
over a longer period of approximately five days submersion of the iodate/
iodide/PVP
loaded tablets ( 1 tabletlml). Each point represents an experiment in which
three tablets
in 3 ml 100 mM citrate, pH 4.0, were submerged for the interval shown, and
then an
aliquot ( 1 ml) of the buffer solution assayed for residual elemental iodine.
Elemental
iodine was quantitated by extracting citrate buffer aliquots in chloroform (1
ml), and
reading the absorbance at 508 nm against a calibration curve constructed with
crystalline
elemental iodine made up in chloroform at known concentrations expressed in
ppm
elemental iodine. While there was significant variability in the generation of
free
elemental iodine over the five day interval examined, elemental iodine ranged
from a low
of approximately 2 ppm to a high of 70 ppm in this series of experiments. The
maximum
elemental iodine level peaked around 36 to 48 hours after submersion of the
tablets in
citrate buffer.
CA 02335055 2000-12-13
WO 99/65538 PCTNS99/13898
Example 5
This example illustrates the fabrication of a hydrogel device embodiment that
is
activated upon contact with aqueous fluids. Two percent "medium viscosity"
sodium
alginate was mixed with an equal volume of 2% Carbopol 971 {B.F. Goodrich)
(cross-
linked polyacrylate) to yield a composite 1 % viscous gel solution, pH 3.95,
made up in
equivalent weights of alginate and Carbopol. This gel mixture was chilled to ~
4 °C.
100 mM potassium iodide made up in water was then mixed thoroughly into the
gel to
yield a final concentration of 1 mM potassium iodide. An equivalent amount of
100 mM
sodium iodate was rapidly mixed into the gel to yield a gel mixture comprised
of 1mM
sodium iodate, 1 mM potassium iodide, 1 % alginate and 1 % Carbopol 971. This
mixture
was quickly frozen at -70 °C, lyophilized overnight under vacuum, and
yielded a fine,
highly porous, lightweight, sponge-like product, red-brown in appearance. The
sponge-
like product was cut into various shapes and left in sealed containers (to
keep out
moisture) at room temperature without loss of its nascent elemental iodine
generating
capacity (that is, upon solvation in aqueous solutions).
Upon addition of water to the sponge-like material, its color changed almost
instantly from red-brown to an intense canary-yellow, revealing rapid
formation of
nascent elemental iodine complexed to iodide in the form of I3-, and it
thickened into a
viscous hydrogel. The presence of nascent elemental iodine was confirmed by
extraction
in chloroform and verification by spectral scanning of the final extract
(e.g., absorbance
max, 508 nm; product lost upon addition of excess reducing agents to the
rehydrated
gel). Various shapes of the sponge-like product were also prepared by freezing
gel
mixtures immediately after addition of iodate and iodide , and before
significant
elemental iodine was allowed to form.
While the rate of elemental iodine formation in the same gel mixtures was very
much slower when first prepared in aqueous form for freezing, following
freezing and
lyophilization, iodate and iodide rapidly produced elemental iodine, as noted,
within
seconds of coming into contact .with aqueous solutions. This was determined to
be the
result of the concentrating effect of lyophilization, such that solvation
allowed for much
higher concentrations of iodate and iodide to interact with one another in
generating
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
61
elemental iodine then was possible prior to the freezing and lyophilization.
After
lyophilization, in the absence of water, iodate and iodide were not free to
interact with
one another pending their solvation. Hence, this embodiment of the invention,
referred
to as the hydrogel device, allowed for incorporation of all of the essential
reactants
within a single matrix (e.g., the hydrogel polymer).
A hydrogel embodiment device was also prepared using glucose oxidase {D-
glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) (i0 pg/ml) and horseradish
peroxidase
(donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7) (3 p.g/ml) mixed into a
1
alginate-Carbopol gel suspension made up in water at room temperature to which
potassium iodide at a final concentration of 2 mM was added. The gel mixture
was
frozen and lyophilized as in the iodate/iodide embodiment. The sponge-like
product (in
this case) exhibited an off white color with a tinge of yellow, and could be
stored for
several weeks at room temperature without loss of nascent elemental iodine
generating
activity triggered by the addition of glucose (~ 50 mg/dl). Controls in which
water was
added in place of glucose solution showed no elemental iodine formed. In both
instances, the sponge-like product quickly solvated to a viscous, mucous-like
hydrogel.
Elemental iodine was confirmed by recovery of elemental iodine in chloroform
extracts
similar to hydrogel delivery devices formulated with iodide and iodate. The
concentration of glucose used to activate the glucose oxidase/horseradish
peroxidase
formulated delivery device was not particularly critical in that solutions as
low as 10
mg/dl and higher concentrations in the range of 100 mg/dl, when added to the
desiccated
gel, triggered nascent elemental iodine formation.
Both embodiments of hydrogel formulations cited in this example showed
formation of nascent elemental iodine ranging from a low of a few ppm to an
upper limit
in the range of 100 ppm. The elemental iodine formation was commensurate with
the
concentrations of glucose oxidase/horseradish peroxidase, or iodide and iodate
incorporated into the hydrogel prior to freezing and iyophilization of the gel
mixtures.
Elemental iodine was seen to persist in the thick gel mixtures for a period of
approximately 8 to 10 hours after which it tapered off to undetectable levels.
Figure 5 shows de novo formation of elemental iodine upon solvation of a
lyophilized 1% "high viscosity" pH 4.0 alginate inventive device embodiment
prepared
CA 02335055 2000-12-13
WO 99/65538 PC'T/US99/13898
62
in the form of a cylinder. The initial formulation comprised a 2 mM potassium
iodide
solution and a 2 mM sodium iodate solution. The gel was cast in 100 (length) x
0.6 cm
(internal diameter) tubes in the frozen state, lyophilized and cut
longitudinally into 1 cm
sections. Control gel was prepared in the same manner but with omission of
iodide and
iodate from the final mixtures. Elemental iodine was measured following 20
minutes
submersion of the alginate formulation ( 1 cm lengths) in 1 ml 100 mM citrate
buffer, pH
4Ø Values shown (Figure 5) represent the average of triplicate experiments
compared
to control results using alginate formulated in the same manner except for the
exclusion
of iodide and iodate from the polymer matrix. Concomitant with the in situ
formation of
elemental iodine, the gel swelled to a viscous, mucous-like, hydrogel
characteristic of its
original composition prior to lyophilization.
Example 6
This example illustrates the exploitation of proton (H+) formation in driving
the
formation of nascent elemental iodine. On chemical grounds, the oxidation of
iodide to
elemental iodine requires H+ as one of the reactants in driving the reaction
to completion
whether iodide is oxidized by H202 or by iodate. This can be fully appreciated
in
considering the stoichiometry of the oxidative reactions illustrated in
equations l and 2
below:
Equation 1 2H+ + 2 I' + H202 -~ IZ + 2H20
Equation 2 6H+ + 5 I' + 1p3- -~ 3I2 + 3H20
It follows that elemental iodine generating formulations designed to enhance
H+
production should facilitate nascent elemental iodine formation in providing
H+ required
in converting iodide into elemental iodine de novo.
Two embodiments were used to demonstrate this principle: one involving H+
formation through the action of glucose oxidase (D-glucose:oxygen 1-
oxidoreductase;
EC 1.1.3.4) on glucose catalyzing concomitant formation of H202 and gluconic
acid; the
other involving spontaneous hydrolysis of the iodine pentoxide resulting in
the
concomitant formation of iodate and H+ (the ionized product of iodic acid). H+
generators
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
63
or donors that allow for this phenomenon are not limited to these two
compounds. They
can include any one or a number of synthetic polyanhydrides, polycarboxylic
compounds, and the like (such as, polylactides, polygalactides, acetic
anhydrides, etc.).
In one formulation, iodine pentoxide was encapsulated within a silicone
device,
prepared as in example 2, but in combination with iodide at a mass ratio of 2%
iodide
and 4% iodine pentoxide substituted in place of iodate. A similar device was
fabricated
using 8% by mass iodate in place of iodine pentoxide. Upon curing the two
devices,
"hole" punch tablets of each cut at approximately 0.6 cm in diameter and 0.3
cm
thickness were submerged at 1 tablet per ml in a total volume of 5 ml 100 mM
sodium
citrate, pH 4Ø The rate of elemental iodine formation was tracked visually
in the buffer
medium by observing the rate of I3- egressing from each tablet. Chloroform
extraction of
the buffer medium was also used to visually confirm the formation of elemental
iodine
(evident in the violet extract recovered in the chloroform layer}.
Tablets obtained from the device formulated with iodine pentoxide in place of
iodate showed more than twice the rate of elemental iodine formed relative to
tablets
obtained from device fabricated with iodate. These data are consistent with
the notion of
solvation of iodine pentoxide as an anhydride and its subsequent rapid
hydrolysis to
HI03 (which can occur with solvation of iodine pentoxide). Therefore, there
was
simultaneous production of H+ and iodate. The faster rates of elemental iodine
formation
seen in the tablets containing iodine pentoxide were attributable to H+
formation. This
conclusion was based upon the observation that the actual available amount of
iodate was
equivalent in both devices (e.g., 4% iodine pentoxide is the equivalent of 8%
iodate
based upon the stoichiometry that two moles of iodate and two moles .of H+ are
released
for every mole of iodine pentoxide solvated), and in consideration of equation
2. These
results further indicate that the formation of elemental iodine was limited by
the available
supply of H+ in solution and validated by fabricating devices formulated with
iodate and
iodide as above, but also including 10% citric acid in the formulation. In the
citric acid
embodiment, the rate of elemental iodine formation exceeded even that seen
with devices
fabricated with iodine pentoxide fonmulations. These data support a notion of
an
abundance of excess H+ solvating via citric acid encapsulation within the
device.
The utility of using H+ production to drive more efficient production of
nascent
CA 02335055 2000-12-13
WO 99/65538 PC'T/US99/i3898
64
elemental iodine was further investigated in the second embodiment.
Specifically, test
solutions using glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC
1.1.3.4) and
glucose in combination with horseradish peroxidase (donor:hydrogen-peroxide
oxidoreductase; EC 1.11.1.7) and iodide were prepared. The rates of nascent
elemental
iodine released were tracked spectrally at pH 4.5 versus pH 7.4. This pH
difference was
chosen because earlier measurements of rates of nascent elemental iodine
formation in
the presence of 1 mM H202, or less, showed that the rate of elemental iodine
formation
was several orders of magnitude slower at pH 7.4 compared to pH 4.5. The pH
observation used HZOz alone mixed with iodide. However, the latter reaction
involved
the consumption of one mole equivalent of molecular OZ and H20 yielding H202
and
gluconic acid. Gluconic acid, as a carboxylic acid like citric acid, is able
to readily
dissociate into its carboxylate anionic form, yielding gluconate, and
providing one H+
equivalent for every mole equivalent of H202 formed in the reaction.
Therefore, H+ can
be generated to enhance elemental iodine formation in accordance with the
reactions
outlined in equation 1. This conclusion is supported by the above-noted data
that tested
rates of elemental iodine formation at the two pH ranges (pH 4.5 and pH 7.4)
and used
glucose and glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) as
a
source for generating H202 oxidant concomitant with H+ production in driving
oxidation
of iodide into elemental iodine. The latter rate measurements were compared
with those
seen without glucose oxidase as the driving reaction in generating H202.
Figure 6 shows that glucose oxidase in combination with glucose accelerated
elemental iodine formation through its capacity to provide H+ at the same time
it
provided H202 oxidant for driving elemental iodine production via the
peroxidative
reaction outlined in equation 1.~ In these experiments, the rate of elemental
iodine
formation was investigated using a fixed concentration of iodide {50 mM) made
up in
100 mM sodium citrate, pH 4.5, also containing 3 U/ml horseradish peroxidase
and 100
mg/dl glucose, and in 10 mM sodium phosphate, pH 7.4, made up in 150 mM NaCI,
100
mg/dl glucose and 3 U/ml horseradish peroxidase, and variable levels of
glucose oxidase
as indicated. Rates of elemental iodine formation were tracked spectrally at
350 nm by
measuring I3 formation at 350 nm on a Shimadzu UV-265 double beam
spectrometer.
Kinetic rates were instantaneous upon addition of glucose oxidase to reaction
mixtures,
CA 02335055 2000-12-13
WO 99/05538 PCT/US99/13898
and linear in excess of 2 Absorbance units per min, and comparable whether
allowed to
occur at pH 4.~ or 7.4. The comparable rates indicate that the oxidation of
iodide was
driven by both H+ and H202 production. H+ was being consumed as quickly as it
was
formed in the enzymatic reaction. However, the formation of elemental iodine
near
neutral pH was primarily limited by available H+ (e.g., there was a H+
deficit).
The data in Figure 6 show comparable rates of elemental iodine formation that
occurred at pH 4.5 versus pH 7.4 and were driven through using glucose oxidase
and
glucose as the source of H20z and H+ formation, allowing for peroxidation of
iodide into
elemental iodine. Moreover, the anhydride studies above, indicate that methods
for
introducing H+ into formulations used in fabricating the inventive
microbicidal devices
improve the de novo rate of formation of elemental iodine. These data
establish that
preferred formulations exploit H+ production by enzymatic mechanisms (e.g.,
glucose
oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4)), or incorporate
anhydrides
(which can serve to hydrolyze upon solvation and egress from the delivery
device such as
with iodine pentoxide), or incorporate polycarboxylic acid H+ donors (e.g.,
alginic acid,
Carbopol or citric acid). Polycarboxylic acid H+ donors are capable of giving
up H+ to
the oxidative reaction involving conversion of iodide into elemental iodine.
Preferred H+
driven formulations more efficiently drive chemical conversion of iodide into
nascent
elemental iodine.
Example 7
This example illustrates the release of iodide and iodate and the formation of
elemental iodine from cannular devices coated with silicone polymer containing
elemental iodine generating iodide/iodate formulations. Figure 7 shows the
kinetic
release of iodide and iodate upon submersion of silicone and polyethylene
tubing coated
on its external surface with a thin layer of silicone elastomer containing
with 2% sodium
iodide, 8 % sodium iodate and 10% PVP prepared prior to curing, as in Example
4. Prior
to curing the formulated silicone elastomer, silicone tubing of 1 cm outer
diameter, and
polyethylene tubing of approximately the same diameter, were each dipped in
the
formulated elastomer, and then allowed to cure overnight at room temperature.
Sections
of 2.5 and 5 cm lengths were cut from the precoated silicone and polyethylene
cannulae,
CA 02335055 2000-12-13
WO 99/65538 PCT/US99/13898
66
rinsed in distilled water, and then submerged in S ml of 100 mM sodium citrate
pH 4Ø
The kinetic release of iodide (dashed lines) and iodate (solid lines) (Figure
7) from the
coated tubing was measured. The thickness of the coating of the formulated
polymer
was not less than 0.08 mm nor greater than 0.15 mm.
Figure 7 shows that using the above formulation, that iodate was released
efficiently from the coated devices, peaking at between 2.5 mM and 4 mM around
24
hours after submersion in the buffer solution. Iodide was also recovered in
the buffer
wash, but at much lower concentrations, in the range of 0.1 to 1.0 mM
depending upon
the substratum to which the polymer formulation had been coated. Polyethylene
yielded
somewhat lower recoveries than silicone as the substratum to which the polymer
formulation had been coated (silicone, filled squares; polyethylene, open
triangles).
After approximately 24 hours, both iodate and iodide began to decline in the
wash
solution. This result indicates a depletion of the elemental iodine generating
formulation
from the base polymer coating laid down on the silicone and polyethylene
substratum.
Elemental iodine was measured within 20 minutes of submerging the tubes in
buffer, and
at approximately the peak range of iodate and iodide in solution at around 24
hours. The
results showed a low of 4 ppm shortly after submersion of the coated devices
in the
buffer, and a peak level of approximately 30 ppm at the latter peak interval.
The results of these tests demonstrate the feasibility of coating and
conferring to
prefabricated devices (in this case cannular tubing) microbicidal nascent
elemental iodine
generating activity. The illustrative device encapsulated the elemental iodine
generating
formulation within a silicone polymeric base, and then cured it to the outer
surface of the
prefabricated devices. The outer surface makes contact with fluid upon
insertion or
placement within an aqueous environment. Therefore, the outer surface is
designed to be
inserted into body cavities.
Example 8
In this example free migration and diffusion of iodine through silicone
polymer is
demonstrated. Polycarbopol (polyacrylates) and potassium monophosphate, as dry
powders, were each separately formulated with iodide and iodate at a 1 % by
weight
composition relative to the silicone elastomer, also made up in 2% sodium
iodide and 8%
CA 02335055 2000-12-13
WO 99/b5538 PCT/US99/13898
67
sodium iodate by weight relative to the silicone elastomer. None of the salts
were
desiccated before scurrying into the silicone polymer to allow for
introduction of
sufficient water to initiate formation of elemental iodine during the curing
process of the
polymer base, and thereafter. Each formulation was cast in a plastic tray in a
rectangular
sheet measuring 8.7 by 11.3 cm and 0.25 cm thick. The catalyst for the
silicone
elastomer (polydimethylsiloxane with silanol end groups, average molecular
weight,
93,000) was dibutyl tin dilaurate. During curing overnight at room
temperature, the trays
were placed in plastic bags sealed so as to prevent moisture from getting to
the trays
from the atmosphere, and to retard loss of iodine from the formulated silicone
sheets. On
the following morning the sheets were seen to be coated with iodine, evident
by a light
red-brown coloration characteristic of iodine. The presence of iodine was
confirmed
spectrally in cutting a strip of silicone from the sheets and immersing each
in water, and
then scanning the sample spectrally for iodine.
To prove iodine was passing freely through the silicone, a strip was cut from
each
sheet enclosed within the plastic bag and placed outside the bag in the open
atmosphere.
Under these conditions the iodine was seen to move freely from the silicone
strip onto
paper strips placed above the cut strips wherein it caused discoloration of
the paper. The
strips were then placed back into the plastic bag and seen to darken up with
the
characteristic color of iodine once they were again sealed from the open
atmosphere.
This cycle was repeated demonstrating the free migration of iodine through
silicone once
formed from within the interior formulation encapsulated in each sheet.
To further verify the free migration of iodine through silicone, a polymer mix
(2% sodium iodide, 8% sodium iodate, 1% potassium monophosphate, undesiccated)
was prepared in two 12 x 75 mm polycarbonate tubes in the silicone elastomer.
Upon
hardening and storage for 5 days, both showed identical brownish-yellow
coloration
indicative of iodine formation (de novo), and the coloration was graded. The
most
intense color was at the bottom of the tube whereas at the very top, exposed
to the
atmosphere, the color was "sea green" typical of polymer low in iodine
content. One
tube was split open to expose the polymer uniformly to the atmosphere. Within
approximately 30 minutes, the polymer opened to the atmosphere showed a
surface
coloration as "sea green" with complete loss of its iodine coloration.
CA 02335055 2000-12-13
WO 99/b5538 PCT/US99/13898
68
A further investigation was undertaken to show that iodine can be produced de
novo from the interior of the polymer base and diffuse freely to the exterior.
Manufactured silastic tubing, 16 cm in length and 0.5 cm in diameter, was
loaded with
0.2 g of a salt mixture ground into a mixture from 0.2 g sodium iodide + 0.8 g
sodium
iodate, and the tubing was sealed into a ring upon then loading the tube with
a 0.5%
solution of polycarbopol. The silicone ring was rinsed and submerged into a
beaker of
30 ml water. Within approximately 5 to 10 min, iodine in the range of 10 to 30
ppm was
seen in the water covering the ring, and iodine continued to egress over a 24
hours period
with sequential rinsing and refilling of the beaker with fresh water (30 ml).
Tests with
dyes showed the ring had a tight seal such that iodine was not escaping at the
juncture
point, but through the silicone wall of the tubing.
Example 9
Several prototype hydrogel membranes were produced by ( 1 ) preparation of
lyophilized hydrogel formulations containing iodide and an oxidant included in
the same
formulation but lacking substrate (e.g., glucose oxidase and peroxidase), or
(2) as
sandwich bilayers, in which the iodide and oxidant formulations were first
prepared in
lyophilized form separately, then compressed together in a hydraulic press to
form a
bilayer membrane. An example of a single bilayer membrane is illustrated by
the
preparation of a 1 % Noveon AA 1, 1 % carboxymethylcellulose hydrogel mixture
made
up in water separated into two equal volumes. A first hydrogel formulation
contained 20
mM potassium iodide along with 100 micrograms per ml glucose. In a second
hydrogel
formulation, glucose oxidase and horseradish peroxidase were added to a final
concentration of 100 and 20 micrograms per ml, respectively (specific
activities: 100,000
mU per mg and 300,000 mU per mg, respectively). The two hydrogel solutions
were
then prechilled to about 4° C, then rapidly mixed together within about
~ seconds. The
mixture was then immediately poured into an 8.7 x 11.3 cm plastic tray and
frozen at -
70° F. While still frozen the sample was then lyophilized for
approximately 36 hours
under high vacuum after which.a sponge-like, slightly tan rectangular membrane
was
recovered from the tray of approximately 0.3 cm thickness. This membrane was
then
placed between two metal plates coated with plastic sheeting and subjected to
6000 lbs
CA 02335055 2000-12-13
WO 99/ø5538 PCTNS99/13898
69
pressure per square inch resulting in the expression of a thin, paper-like
membrane of
approximately 9 x 13 cm and 0.02 cm thick. The membrane was easily cut into
various
shapes with a pair of scissors, hole punch, or other suitable shearing device,
and in this
form remained dormant with regard to generating elemental iodine for several
months
without apparent loss in iodine generating activity. Upon exposure to water,
elemental
iodine was observed to form within less than 60 seconds, and could be seen to
be present
in the gel-sol over a period of several hours following hydration of the
membrane.
The same two formulations as above were prepared in separate membranes by
lyophilizing each hydrogel containing either iodide and glucose, or glucose
oxidase and
horseradish peroxidase, separately, resulting in the recovery of lyophilized
hydrogels of
the iodide/glucose and enzyme oxidases in separate membranes. To form a
bilayer
sandwich, the two membranes were placed one on top of the other and then
inserted into
the hydraulic press. Upon applying pressure to the sandwiched membranes (6000
lbs per
square inch), the two membranes adhered together as a bilayer membrane (one
side
containing the iodide formulation and the other the enzyme oxidases). This
bilayer
membrane came out of the press in a rectangular form of approximately 9 x 12
cm and
0.02 thickness, and was easily cut with scissors or a hole punch into various
shapes.
Similarly, it proved stable when stored at room temperature for several months
without
apparent loss in iodine generating activity. The latter was seen to form
quickly in less
than 60 seconds upon exposure of the bilayer membrane to water.
Varying other formulations such as the preparation of 3% hydroxypropylmethyl
cellulose, 1 % Noveon AA 1 hydrogels made up in 10 mM potassium iodide, 10 mg
per
ml glucose, and the same hydrogel made up in 100 and 20 microgram per ml
glucose
oxidase and horseradish peroxidase, respectively, or alternatively made up in
20 mM
sodium iodate as the oxidant component, were made and fabricated in the form
of
pressed membranes using the same techniques, confirming the general principles
of this
fabrication technique. The final products were all found to be very
lightweight, and
stable, yet readily produced elemental iodine with wetting of the hydrogel
membranes.
Example 10
To evaluate retention of formulations within the mechanical-release device in
its
CA 02335055 2000-12-13
WO 99155538 PCTNS99/13898
relaxed (e.g., undistorted, static) state, the delivery device was fabricated
as described
herein. Specifically, a siliastic tubing was filled with various indicators.
then submerged
in wash solutions to test for leakage into the external medium bathing the
device. A
device containing approximately 10 holes per square cm was used in these
tests.
In the first experiment, an aqueous solution of toluidine blue (50 ug/ml) was
loaded into the inner reservoir, and following closure of the tubing into the
ring
configuration, the device was rinsed in distilled water, then submerged in SO
ml of 10
mM sodium phosphate buffer, 150 mM NaCI, pH 7.4, placed in a 150 ml glass
beaker
and left to mix about at the base of the beaker on a rocking shaker over a
period of two
weeks. The external buffer was examined visually for any presence of the dye
egressing
from the inner reservoir. None was observed to cross through the perforation
holes into
the external medium under these conditions. Midway through the two week
interval, the
device was gently squeezed and contorted. Dye flowed readily into the external
medium,
but ceased flowing when agitation of the ring was stopped. At this point, the
ring was
removed from the buffer medium, rinsed under distilled water, and placed back
into the
beaker on the rocking shaker with a fresh change of buffer. No additional dye
was seen
to egress from the device until the end of the experiment at which time the
ring was once
again squeezed and distorted beyond its normal resting state configuration.
With this
action dye once again egressed from the inner reservoir.
In a second set of experiments, glucose oxidase (D-glucose:oxygen 1-
oxidoreductase; EC 1.1.3.4) ( 1 mg/ml) and horseradish peroxidase
(donor:hydrogen-
peroxide oxidoreductase; EC 1.11.1.7) (0.5 mg/ml) made up in 10 mM sodium
phosphate buffer, 150 mM NaCI, pH 7.4, was loaded into the inner reservoir of
the
mechanical device. The device ring was closed and rinsed under distilled
water. The
device was then placed in a beaker containing approximately 20 ml 150 mM
potassium
iodide and 100 mg/ml glucose made up in distilled water. No formation of
elemental
iodine, evident by the appearance of the yellow triiodide complex, occurred in
the
external medium even after leaving the ring submerged in the solution over a
period of
approximately 8 hours. At the .end of the experiment, the ring was squeezed
about its
outer circumference to distort its shape into an ellipsoid. This latter
operation triggered
the appearance of triiodide in the external medium (verified as elemental
iodine by
CA 02335055 2000-12-13
WO 99/65538 _. PCTNS99/13898
71
chloroform extraction and identification of its characteristic violet color in
chloroform),
indicating that egress of glucose oxidase and horseradish peroxidase had
occurred as a
result of distortion of the ring, presenting the enzymes formerly contained
within the
inner reservoir to the substrates in the external medium. This allows for
elemental iodine
to be formed via oxidation of glucose and subsequent peroxidation of iodide in
the
external medium.
Both of the foregoing experiments confirm the self sealing properties, and
design,
of the mechanical-release device in retaining formulations placed within its
inner
reservoir, and the elasticity of the pores in resealing and retaining the
formulations within
the inner reservoir upon cessation of mechanical action on the delivery
device.
Example 11
Figure 9 shows the activity of elemental iodine formed enzymatically through
the
action of glucose oxidase (D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) and
horseradish peroxidase (donor:hydrogen-peroxide oxidoreductase; EC 1.11.1.7)
on
glucose and potassium iodide in immobilizing human sperm. In these experiments
glucose oxidase was set at 416 ug/ml, horseradish peroxidase was at 17 ug/ml,
iodide
was held constant at 63 mM, and glucose was 11.6 mM, all made up in 10 mM
sodium
phosphate, 1 SO mM NaCI, pH 7.4 (test reactant mixture). Freshly collected
semen was
diluted 6-fold in isotonic saline made up in 10 mM sodium phosphate buffer, pH
7.4, and
sperm motility scored within 20 seconds of mixing semen with the test
reactants.
Washing the sperm free of the formulations used in these experiments failed to
restore
sperm motility indicating irreversible immobilization of the sperm. Omission
of iodide,
or either horseradish peroxidase or glucose oxidase, from the test reactant to
which sperm
were added resulted in retention of sperm motility (Figure 9). Sperm
immobilization was
complete within 20 seconds in accordance with WHO standards using the modified
Sander-Cramer sperm motility assay in scoring test specimens. Error bars
indicate ~ 1
SD of duplicate determinations of a single donor. Comparable results were
obtained on
six separate donor specimens obtained on samples of four individual sperm
donors. All
sperm samples tested met normal standard characteristics for assessment of
sperm
motility (> 20 x 106 sperm/ml, > 50% motility and > 50% normal forms).
CA 02335055 2000-12-13
WO 99/b5538 PCTNS99/13898
T'
While the invention has been described in terms of certain preferred
embodiments, those skilled in the art will recognize that modifications and
improvements
may be made to the invention without departing form the scope thereof. For
example,
while discussed primarily in terms of elemental iodine generating
formulations, other
oxidant generating formulation may be used as well.
